≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Early syphilis

EFO Endpoint Browser PheWeb

AB1_EARLY_SYPHILIS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — A51
  • Hospital discharge: ICD-9 — 09[1]
  • Hospital discharge: ICD-8 — 09[1]
  • Cause of death: ICD-10 — A51
  • Cause of death: ICD-9 — 09[1]
  • Cause of death: ICD-8 — 09[1]

2 out of 7 registries used, show all original rules.

455

4. Check minimum number of events

None

455

5. Include endpoints

None

455

6. Filter based on genotype QC (FinnGen only)

413

Control definitions (FinnGen only)

Control exclude
AB1_SEXUAL_TRANSMISSION

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF5

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2515 815 1643
Only index persons 2222 742 1480
Unadjusted period prevalence (%)
Whole population 0.04 0.02 0.05
Only index persons 0.05 0.03 0.06
Median age at first event (years)
Whole population 36.88 33.67 38.63
Only index persons 36.48 32.83 38.31

-FinnGen-

Key figures

All Female Male
Number of individuals 413 109 304
Unadjusted period prevalence (%) 0.11 0.04 0.14
Median age at first event (years) 39.47 32.21 42.08

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
455
Matched controls
4550
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Z11.3
ICD-10 Finland
Special screening examination for infections with a predominantly sexual mode of transmission
31.3
287.9
225
138
B23.1
ICD-10 Finland
HIV disease resulting in (persistent) generalized lymphadenopathy
153.6
230.9
115
10
A51.0
ICD-10 Finland
Primary genital syphilis
+∞
201.5
178
*
WW200
NOMESCO Finland
Immunization
29.6
157.7
111
49
A51.3
ICD-10 Finland
Secondary syphilis of skin and mucous membranes
+∞
156.5
141
*
A56.0
ICD-10 Finland
Chlamydial infection of lower genitourinary tract
66.0
154.3
86
16
A56.3
ICD-10 Finland
Chlamydial infection of anus and rectum
1478.4
120.6
112
*
A63.0
ICD-10 Finland
Anogenital (venereal) warts
37.4
110.2
70
22
A54.6
ICD-10 Finland
Gonococcal infection of anus and rectum
+∞
100.9
93
*
Y25
ICPC
Fear sexually transm disease male
11.6
91.6
106
116
A51.9
ICD-10 Finland
Early syphilis, unspecified
+∞
89.6
83
*
A54.5
ICD-10 Finland
Gonococcal pharyngitis
994.8
86.6
82
*
A54.0
ICD-10 Finland
Gonococcal infection of lower genitourinary tract without periurethral or accessory gland abscess
+∞
68.5
64
*
Z29.2
ICD-10 Finland
Other prophylactic chemotherapy
132.6
55.2
58
5
Z21
ICD-10 Finland
Asymptomatic human immunodeficiency virus [HIV] infection status
199.4
52.1
53
*
A53.9
ICD-10 Finland
Syphilis, unspecified
+∞
49.9
47
*
B24
ICD-10 Finland
Unspecified human immunodeficiency virus [HIV] disease
87.0
49.1
54
7
09100
ICD-8 Finland
Early syphilis, symptomatic, Primary syphilis, except extragenital chancre
+∞
43.4
41
*
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
5.0
34.7
84
196
A56.4
ICD-10 Finland
Chlamydial infection of pharynx
+∞
27.4
26
*
A51.5
ICD-10 Finland
Early syphilis, latent
+∞
26.3
25
*
Z3231
NOMESCO Finland
Registered nurse
2.9
24.3
161
723
0913A
ICD-9 Finland
Early syphilis, symptomatic, Secondary syphilis of skin or mucous membranes
+∞
24.2
23
*
Y71
ICPC
Gonorrhoea male
+∞
23.1
22
*
Y70
ICPC
Syphilis male
+∞
22.1
21
*
Z25.1
ICD-10 Finland
Need for immunization against influenza
5.2
21.8
47
98
Z2221
NOMESCO Finland
Medical doctor
2.8
21.3
150
689
A60.0
ICD-10 Finland
Herpesviral infection of genitalia and urogenital tract
19.0
21.2
32
18
09120
ICD-8 Finland
Early syphilis, symptomatic, Secondary syphilis of skin and mucous membranes
+∞
21.0
20
*
B23.8
ICD-10 Finland
HIV disease resulting in other specified conditions
109.9
19.7
21
*
Z20.2
ICD-10 Finland
Contact with and exposure to infections with a predominantly sexual mode of transmission
6.4
18.8
32
53
D06BB04
ATC
podophyllotoxin; topical
4.5
17.7
46
112
B23.0
ICD-10 Finland
Acute HIV infection syndrome
+∞
16.8
16
*
J01MA02
ATC
ciprofloxacin; systemic
2.3
16.6
196
1121
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
4.9
16.4
37
80
ZX114
NOMESCO Finland
Intramuscular
13.6
15.9
27
21
A51.4
ICD-10 Finland
Other secondary syphilis
+∞
15.7
15
*
A55
ICD-10 Finland
Chlamydial lymphogranuloma (venereum)
+∞
15.7
15
*
J05AB11
ATC
valaciclovir; oral
2.8
15.5
91
374
D11
ICPC
Diarrhoea
2.9
15.3
84
333
EB1AA, ,
SPAT
3.7
14.9
49
142
Y99
ICPC
Genital disease male other
23.2
14.3
20
9
ULA02
NOMESCO Finland
Kolposcopy
4.3
13.5
36
89
TAB00
NOMESCO Finland
Lumbar puncture
3.9
12.8
39
107
WX110, ,
SPAT
3.6
12.5
43
128
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.1
11.8
143
805
A52.1
ICD-10 Finland
Symptomatic neurosyphilis
+∞
11.5
11
*
J05AB01
ATC
aciclovir; systemic
2.3
11.4
105
528
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.2
11.4
110
565
Z71.8
ICD-10 Finland
Other specified counselling
2.0
11.2
171
1046
EB1SA, ,
SPAT
3.6
11.1
38
113
A52.9
ICD-10 Finland
Late syphilis, unspecified
+∞
10.5
10
*
A54.9
ICD-10 Finland
Gonococcal infection, unspecified
+∞
10.5
10
*
WNF00
NOMESCO Finland
Infection source and contact determination
33.4
10.4
13
*
WX290, ,
SPAT
4.3
10.3
27
66
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
4.6
10.1
24
54
Z20.6
ICD-10 Finland
Contact with and exposure to human immunodeficiency virus [HIV]
26.7
9.9
13
5
A97
ICPC
No disease
2.2
9.8
101
530
J01AA02
ATC
doxycycline; systemic
2.0
9.7
346
2765
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
11.7
9.6
17
15
Z03
ICD-10 Finland
Medical observation and evaluation for suspected diseases and conditions, ruled out
2.9
9.4
45
164
J01FA10
ATC
azithromycin; systemic
1.9
9.4
271
2009
J01DB01
ATC
cefalexin; oral
2.3
9.2
387
3247
I84
ICD-10 Finland
Hemorrhoids
4.9
9.1
20
42
Z76.0
ICD-10 Finland
Issue of repeat prescription
1.9
8.9
138
836
F43.29
ICD-10 Finland
Adaptation disorder UNS
4.7
8.7
20
44
U07
ICPC
Urine symptom/complaint other
2.9
8.6
40
144
A56.2
ICD-10 Finland
Chlamydial infection of genitourinary tract, unspecified
28.1
8.5
11
*
N48.1
ICD-10 Finland
Balanoposthitis
3.4
8.5
31
96
0910A
ICD-9 Finland
Early syphilis, symptomatic, Genital syphilis (primary)
+∞
8.4
8
*
A53.0
ICD-10 Finland
Latent syphilis, unspecified as early or late
+∞
8.4
8
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.0
8.0
99
552
EMB10
NOMESCO Finland
Tonsillectomy
3.0
8.0
36
127
K03.65
ICD-10 Finland
Deposits [accretions] on teeth betel
1.9
7.7
111
652
B17.1
ICD-10 Finland
Acute hepatitis C
25.5
7.6
10
*
LDA10
NOMESCO Finland
Curettage of cervix uteri
7.0
7.4
17
25
A51.1
ICD-10 Finland
Primary anal syphilis
+∞
7.3
7
*
A03.3
ICD-10 Finland
Shigellosis due to Shigella sonnei
+∞
7.3
7
*
A03.1
ICD-10 Finland
Shigellosis due to Shigella flexneri
+∞
7.3
7
*
LEB00
NOMESCO Finland
Biopsy of vagina
9.0
7.1
14
16
K62.5
ICD-10 Finland
Haemorrhage of anus and rectum
3.1
7.1
29
97
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.1
7.0
68
346
J35.0
ICD-10 Finland
Chronic tonsillitis
3.0
6.9
31
109
B37.4
ICD-10 Finland
Candidiasis of other urogenital sites
17.0
6.8
10
6
R83
ICPC
Respiratory infection other
1.8
6.7
136
887
N48.8
ICD-10 Finland
Other specified disorders of penis
8.9
6.6
13
15
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
2.5
6.6
41
172
N05BA04
ATC
oxazepam; oral
1.8
6.5
111
687
N06AX11
ATC
mirtazapine; oral
1.7
6.4
155
1058
LDC03
NOMESCO Finland
Conisation of cervix uteri using diathermy or laser
6.7
6.4
15
23
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.4
6.3
42
182
D06AX01
ATC
fusidic acid; topical
2.3
6.3
49
228
A52.8
ICD-10 Finland
Late syphilis, latent
+∞
6.3
6
*
A52.3
ICD-10 Finland
Neurosyphilis, unspecified
+∞
6.3
6
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
2.3e+00
2.7e+00
4.6e+00
—
5.2e+00
3.9e+00
2.9e+00
cases:33.33%
controls:4.81%
cases:23.96%
controls:2.06%
cases:29.17%
controls:0.42%
—
—
cases:37.08%
controls:0.31%
cases:49.60%
controls:1.88%
cases:49.85%
controls:5.21%
128
184
256
3643
92
79
292
3748
112
16
272
3811
—
142
12
241
3809
187
71
190
3710
170
178
171
3239
Venereal disease screening
171128005 [4064905]
3.8e+00
4.0e+00
—
1.0e+50
—
5.1e+00
5.0e+00
cases:21.35%
controls:0.63%
cases:13.80%
controls:0.29%
—
—
cases:1.30%
controls:0.00%
—
—
cases:18.57%
controls:0.13%
cases:35.48%
controls:0.38%
82
24
302
3803
53
11
331
3816
—
5
0
379
3827
—
70
5
307
3776
121
13
220
3404
Protein [Mass/volume] in Urine
2888-6 [3037121]
4.0e+00
4.1e+00
—
—
—
4.5e+00
4.7e+00
cases:11.72%
controls:0.24%
cases:7.03%
controls:0.13%
—
—
—
—
—
—
cases:12.20%
controls:0.16%
cases:22.87%
controls:0.26%
45
9
339
3818
27
5
357
3822
—
—
—
46
6
331
3775
78
9
263
3408
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
2.4e+00
3.1e+00
4.6e+00
1.0e+50
—
3.3e+00
3.2e+00
cases:19.79%
controls:2.19%
cases:14.84%
controls:0.81%
cases:11.20%
controls:0.13%
cases:2.34%
controls:0.00%
—
—
cases:18.83%
controls:0.85%
cases:34.02%
controls:2.14%
76
84
308
3743
57
31
327
3796
43
5
341
3822
9
0
375
3827
—
71
32
306
3749
116
73
225
3344
Infectious Disease
44 [38004484]
3.3e+00
4.1e+00
—
1.0e+50
—
5.1e+00
3.8e+00
cases:23.18%
controls:1.10%
cases:21.88%
controls:0.44%
—
—
cases:9.64%
controls:0.00%
—
—
cases:28.65%
controls:0.24%
cases:32.84%
controls:1.11%
89
42
295
3785
84
17
300
3810
—
37
0
347
3827
—
108
9
269
3772
112
38
229
3379
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
1.7e+00
2.4e+00
4.4e+00
1.0e+50
2.9e+00
2.8e+00
1.7e+00
cases:18.75%
controls:4.02%
cases:16.41%
controls:1.78%
cases:18.75%
controls:0.29%
cases:2.86%
controls:0.00%
cases:2.87%
controls:0.16%
cases:20.95%
controls:1.53%
cases:20.82%
controls:4.39%
72
154
312
3673
63
68
321
3759
72
11
312
3816
11
0
373
3827
11
6
372
3815
79
58
298
3723
71
150
270
3267
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
2.0e+00
2.7e+00
5.3e+00
1.0e+50
—
3.2e+00
2.4e+00
cases:23.18%
controls:3.81%
cases:20.83%
controls:1.70%
cases:21.61%
controls:0.13%
cases:5.73%
controls:0.00%
—
—
cases:23.61%
controls:1.30%
cases:29.33%
controls:3.54%
89
146
295
3681
80
65
304
3762
83
5
301
3822
22
0
362
3827
—
89
49
288
3732
100
121
241
3296
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
2.3e+00
3.0e+00
3.6e+00
—
—
3.1e+00
2.7e+00
cases:9.90%
controls:1.07%
cases:11.20%
controls:0.60%
cases:4.69%
controls:0.13%
—
—
—
—
cases:14.59%
controls:0.74%
cases:21.41%
controls:1.73%
38
41
346
3786
43
23
341
3804
18
5
366
3822
—
—
55
28
322
3753
73
59
268
3358
Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
24111-7 [3011371]
3.3e+00
3.7e+00
—
1.0e+50
—
4.0e+00
3.5e+00
cases:17.71%
controls:0.81%
cases:17.71%
controls:0.52%
—
—
cases:10.16%
controls:0.00%
—
—
cases:22.02%
controls:0.53%
cases:27.57%
controls:1.14%
68
31
316
3796
68
20
316
3807
—
39
0
345
3827
—
83
20
294
3761
94
39
247
3378
Treponema pallidum Ab [Titer] in Serum by Hemagglutination
26009-1 [3019539]
4.2e+00
—
1.0e+50
1.0e+50
1.0e+50
5.3e+00
4.9e+00
cases:9.90%
controls:0.16%
—
—
cases:26.82%
controls:0.00%
cases:7.29%
controls:0.00%
cases:3.39%
controls:0.00%
cases:20.95%
controls:0.13%
cases:28.45%
controls:0.29%
38
6
346
3821
—
103
0
281
3827
28
0
356
3827
13
0
370
3821
79
5
298
3776
97
10
244
3407
Outpatient Visit
OP [9202]
6.4e-01
7.8e-01
1.2e+00
6.3e+00
2.4e+00
1.5e+00
8.7e-01
cases:69.53%
controls:54.64%
cases:52.60%
controls:33.71%
cases:20.57%
controls:7.03%
cases:46.09%
controls:0.16%
cases:44.13%
controls:6.62%
cases:68.97%
controls:32.66%
cases:80.65%
controls:63.54%
267
2091
117
1736
202
1290
182
2537
79
269
305
3558
177
6
207
3821
169
253
214
3568
260
1235
117
2546
275
2171
66
1246
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
2.9e+00
3.4e+00
—
1.0e+50
—
3.9e+00
3.4e+00
cases:18.75%
controls:1.20%
cases:18.23%
controls:0.71%
—
—
cases:10.16%
controls:0.00%
—
—
cases:22.55%
controls:0.58%
cases:27.86%
controls:1.32%
72
46
312
3781
70
27
314
3800
—
39
0
345
3827
—
85
22
292
3759
95
45
246
3372
Treatment of a patient needing special arrangements
WYA30 [2001310874]
2.3e+00
3.0e+00
—
—
—
3.8e+00
3.1e+00
cases:6.51%
controls:0.71%
cases:3.91%
controls:0.21%
—
—
—
—
—
—
cases:5.57%
controls:0.13%
cases:10.26%
controls:0.53%
25
27
359
3800
15
8
369
3819
—
—
—
21
5
356
3776
35
18
306
3399
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.1e+00
1.9e+00
2.9e+00
—
2.2e+00
2.2e+00
1.6e+00
cases:11.98%
controls:4.34%
cases:11.98%
controls:2.01%
cases:5.21%
controls:0.29%
—
—
cases:2.09%
controls:0.24%
cases:16.18%
controls:2.17%
cases:25.51%
controls:6.61%
46
166
338
3661
46
77
338
3750
20
11
364
3816
—
8
9
375
3812
61
82
316
3699
87
226
254
3191
Short blood count panel - Blood
55429-5 [40758558]
1.5e+00
1.7e+00
2.4e+00
—
1.9e+00
2.3e+00
1.8e+00
cases:13.54%
controls:3.32%
cases:8.33%
controls:1.67%
cases:3.13%
controls:0.29%
—
—
cases:2.09%
controls:0.31%
cases:11.41%
controls:1.32%
cases:19.65%
controls:3.75%
52
127
332
3700
32
64
352
3763
12
11
372
3816
—
8
12
375
3809
43
50
334
3731
67
128
274
3289
Fear sexually transm disease male
Y25 [2002001393]
2.5e+00
2.8e+00
—
—
—
3.2e+00
2.8e+00
cases:8.85%
controls:0.76%
cases:4.17%
controls:0.26%
—
—
—
—
—
—
cases:4.24%
controls:0.19%
cases:8.50%
controls:0.59%
34
29
350
3798
16
10
368
3817
—
—
—
16
7
361
3774
29
20
312
3397
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
2.4e+00
2.7e+00
—
—
1.0e+50
2.8e+00
2.9e+00
cases:12.24%
controls:1.28%
cases:7.03%
controls:0.50%
—
—
—
—
cases:1.31%
controls:0.00%
cases:10.34%
controls:0.71%
cases:21.99%
controls:1.49%
47
49
337
3778
27
19
357
3808
—
—
5
0
378
3821
39
27
338
3754
75
51
266
3366
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
2.6e+00
3.2e+00
—
1.0e+50
—
2.7e+00
2.2e+00
cases:17.97%
controls:1.59%
cases:16.93%
controls:0.86%
—
—
cases:5.73%
controls:0.00%
—
—
cases:9.28%
controls:0.69%
cases:17.60%
controls:2.31%
69
61
315
3766
65
33
319
3794
—
22
0
362
3827
—
35
26
342
3755
60
79
281
3338
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
2.0e+00
2.7e+00
—
1.0e+50
—
3.2e+00
2.4e+00
cases:20.57%
controls:3.37%
cases:19.01%
controls:1.59%
—
—
cases:4.69%
controls:0.00%
—
—
cases:21.75%
controls:1.14%
cases:28.45%
controls:3.39%
79
129
305
3698
73
61
311
3766
—
18
0
366
3827
—
82
43
295
3738
97
116
244
3301
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
1.1e+00
1.4e+00
2.2e+00
—
2.2e+00
1.7e+00
1.4e+00
cases:13.28%
controls:4.68%
cases:10.42%
controls:2.72%
cases:4.17%
controls:0.50%
—
—
cases:3.13%
controls:0.37%
cases:13.00%
controls:2.64%
cases:25.81%
controls:7.67%
51
179
333
3648
40
104
344
3723
16
19
368
3808
—
12
14
371
3807
49
100
328
3681
88
262
253
3155
sildenafil; oral
G04BE03 [21602648]
1.3e+00
1.5e+00
2.0e+00
—
2.0e+00
1.7e+00
1.5e+00
cases:9.38%
controls:2.85%
cases:9.38%
controls:2.33%
cases:3.91%
controls:0.52%
—
—
cases:3.13%
controls:0.44%
cases:11.14%
controls:2.22%
cases:21.70%
controls:5.94%
36
109
348
3718
36
89
348
3738
15
20
369
3807
—
12
17
371
3804
42
84
335
3697
74
203
267
3214
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.1e+00
1.5e+00
2.3e+00
—
1.6e+00
1.8e+00
1.5e+00
cases:15.63%
controls:5.83%
cases:14.58%
controls:3.53%
cases:6.77%
controls:0.73%
—
—
cases:3.39%
controls:0.68%
cases:18.57%
controls:3.57%
cases:27.86%
controls:7.67%
60
223
324
3604
56
135
328
3692
26
28
358
3799
—
13
26
370
3795
70
135
307
3646
95
262
246
3155
Differential panel, method unspecified - Blood
69738-3 [42870588]
9.2e-01
1.6e+00
2.1e+00
—
1.5e+00
1.8e+00
1.9e+00
cases:9.38%
controls:3.95%
cases:10.68%
controls:2.38%
cases:4.43%
controls:0.55%
—
—
cases:2.35%
controls:0.52%
cases:13.26%
controls:2.41%
cases:24.05%
controls:4.51%
36
151
348
3676
41
91
343
3736
17
21
367
3806
—
9
20
374
3801
50
91
327
3690
82
154
259
3263
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.1e+00
1.5e+00
2.2e+00
—
1.6e+00
1.8e+00
1.5e+00
cases:15.63%
controls:5.83%
cases:14.58%
controls:3.53%
cases:6.51%
controls:0.73%
—
—
cases:3.39%
controls:0.68%
cases:18.57%
controls:3.62%
cases:27.86%
controls:7.64%
60
223
324
3604
56
135
328
3692
25
28
359
3799
—
13
26
370
3795
70
137
307
3644
95
261
246
3156
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.1e+00
1.5e+00
2.2e+00
—
1.6e+00
1.8e+00
1.5e+00
cases:15.63%
controls:5.80%
cases:14.58%
controls:3.53%
cases:6.51%
controls:0.73%
—
—
cases:3.39%
controls:0.68%
cases:18.57%
controls:3.62%
cases:27.86%
controls:7.70%
60
222
324
3605
56
135
328
3692
25
28
359
3799
—
13
26
370
3795
70
137
307
3644
95
263
246
3154
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
1.1e+00
1.5e+00
2.3e+00
—
1.6e+00
1.8e+00
1.5e+00
cases:16.41%
controls:5.91%
cases:14.84%
controls:3.61%
cases:6.77%
controls:0.76%
—
—
cases:3.39%
controls:0.73%
cases:18.57%
controls:3.78%
cases:27.57%
controls:7.70%
63
226
321
3601
57
138
327
3689
26
29
358
3798
—
13
28
370
3793
70
143
307
3638
94
263
247
3154
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.1e+00
1.5e+00
2.2e+00
—
1.6e+00
1.7e+00
1.5e+00
cases:16.41%
controls:6.17%
cases:14.58%
controls:3.68%
cases:6.77%
controls:0.78%
—
—
cases:3.39%
controls:0.71%
cases:18.57%
controls:3.89%
cases:27.86%
controls:8.08%
63
236
321
3591
56
141
328
3686
26
30
358
3797
—
13
27
370
3794
70
147
307
3634
95
276
246
3141
Normoblasts [#/volume] in Blood
715-3 [3021589]
1.2e+00
1.4e+00
2.1e+00
—
1.7e+00
1.8e+00
1.5e+00
cases:13.54%
controls:4.52%
cases:13.28%
controls:3.53%
cases:5.99%
controls:0.81%
—
—
cases:3.39%
controls:0.65%
cases:17.51%
controls:3.54%
cases:25.81%
controls:7.37%
52
173
332
3654
51
135
333
3692
23
31
361
3796
—
13
25
370
3796
66
134
311
3647
88
252
253
3165
Reagin Ab [Titer] in Serum by VDRL
50690-7 [3029634]
4.1e+00
—
1.0e+50
1.0e+50
1.0e+50
—
5.2e+00
cases:10.16%
controls:0.18%
—
—
cases:28.91%
controls:0.00%
cases:8.85%
controls:0.00%
cases:8.36%
controls:0.00%
—
—
cases:37.24%
controls:0.32%
39
7
345
3820
—
111
0
273
3827
34
0
350
3827
32
0
351
3821
—
127
11
214
3406
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.1e+00
1.4e+00
2.2e+00
—
1.5e+00
1.7e+00
1.4e+00
cases:15.63%
controls:5.91%
cases:14.32%
controls:3.92%
cases:6.77%
controls:0.84%
—
—
cases:3.39%
controls:0.76%
cases:18.57%
controls:3.99%
cases:28.15%
controls:8.55%
60
226
324
3601
55
150
329
3677
26
32
358
3795
—
13
29
370
3792
70
151
307
3630
96
292
245
3125
Basophils [#/volume] in Blood
26444-0 [3006315]
1.1e+00
1.4e+00
2.1e+00
—
1.5e+00
1.7e+00
1.4e+00
cases:15.63%
controls:5.91%
cases:14.32%
controls:3.92%
cases:6.51%
controls:0.84%
—
—
cases:3.39%
controls:0.76%
cases:18.57%
controls:4.02%
cases:28.15%
controls:8.55%
60
226
324
3601
55
150
329
3677
25
32
359
3795
—
13
29
370
3792
70
152
307
3629
96
292
245
3125
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
1.1e+00
1.4e+00
2.1e+00
—
1.5e+00
1.7e+00
1.4e+00
cases:16.67%
controls:6.30%
cases:14.58%
controls:4.05%
cases:6.77%
controls:0.89%
—
—
cases:3.39%
controls:0.79%
cases:18.57%
controls:4.18%
cases:28.15%
controls:8.93%
64
241
320
3586
56
155
328
3672
26
34
358
3793
—
13
30
370
3791
70
158
307
3623
96
305
245
3112
Eosinophils [#/volume] in Blood
26449-9 [3013115]
1.1e+00
1.4e+00
2.1e+00
—
1.4e+00
1.7e+00
1.4e+00
cases:15.89%
controls:6.11%
cases:14.58%
controls:4.10%
cases:6.77%
controls:0.86%
—
—
cases:3.39%
controls:0.86%
cases:18.57%
controls:4.05%
cases:28.45%
controls:8.78%
61
234
323
3593
56
157
328
3670
26
33
358
3794
—
13
33
370
3788
70
153
307
3628
97
300
244
3117
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
1.3e+00
1.6e+00
3.2e+00
—
—
1.6e+00
1.2e+00
cases:7.55%
controls:2.22%
cases:4.95%
controls:1.02%
cases:4.43%
controls:0.18%
—
—
—
—
cases:5.04%
controls:1.06%
cases:8.80%
controls:2.84%
29
85
355
3742
19
39
365
3788
17
7
367
3820
—
—
19
40
358
3741
30
97
311
3320
Laboratory Visit
OMOP4822461 [32036]
1.6e-01
5.4e-01
2.1e+00
4.4e+00
1.1e+00
7.9e-01
1.4e-01
cases:32.29%
controls:28.82%
cases:36.20%
controls:24.77%
cases:34.64%
controls:6.38%
cases:17.97%
controls:0.26%
cases:16.71%
controls:6.28%
cases:43.77%
controls:26.18%
cases:46.63%
controls:43.14%
124
1103
260
2724
139
948
245
2879
133
244
251
3583
69
10
315
3817
64
240
319
3581
165
990
212
2791
159
1474
182
1943
Need for immunization against influenza
Z25.1 [45581017]
2.2e+00
2.5e+00
—
—
—
2.2e+00
1.7e+00
cases:3.13%
controls:0.34%
cases:1.82%
controls:0.16%
—
—
—
—
—
—
cases:1.86%
controls:0.21%
cases:2.93%
controls:0.56%
12
13
372
3814
7
6
377
3821
—
—
—
7
8
370
3773
10
19
331
3398
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
1.0e+00
1.3e+00
1.8e+00
—
1.3e+00
1.6e+00
1.3e+00
cases:17.45%
controls:6.95%
cases:15.36%
controls:4.83%
cases:6.77%
controls:1.15%
—
—
cases:3.92%
controls:1.05%
cases:19.10%
controls:4.58%
cases:28.74%
controls:9.66%
67
266
317
3561
59
185
325
3642
26
44
358
3783
—
15
40
368
3781
72
173
305
3608
98
330
243
3087
Emergency Room Visit
ER [9203]
7.6e-01
1.1e+00
3.0e+00
—
1.4e+00
1.1e+00
9.4e-01
cases:40.10%
controls:23.86%
cases:20.05%
controls:8.05%
cases:17.97%
controls:1.10%
—
—
cases:3.13%
controls:0.81%
cases:19.10%
controls:7.04%
cases:43.11%
controls:22.80%
154
913
230
2914
77
308
307
3519
69
42
315
3785
—
12
31
371
3790
72
266
305
3515
147
779
194
2638
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
2.3e+00
1.3e+00
—
—
—
3.1e+00
2.3e+00
cases:7.55%
controls:0.78%
cases:1.82%
controls:0.52%
—
—
—
—
—
—
cases:5.04%
controls:0.24%
cases:10.85%
controls:1.23%
29
30
355
3797
7
20
377
3807
—
—
—
19
9
358
3772
37
42
304
3375
Leukocytes [#/volume] in Urine
30405-5 [3018095]
1.2e+00
1.0e+00
2.1e+00
—
—
1.7e+00
1.6e+00
cases:7.81%
controls:2.53%
cases:4.69%
controls:1.70%
cases:1.82%
controls:0.24%
—
—
—
—
cases:7.69%
controls:1.51%
cases:18.18%
controls:4.45%
30
97
354
3730
18
65
366
3762
7
9
377
3818
—
—
29
57
348
3724
62
152
279
3265
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
8.2e-01
1.3e+00
2.5e+00
—
—
2.0e+00
1.5e+00
cases:3.39%
controls:1.52%
cases:3.39%
controls:0.97%
cases:1.56%
controls:0.13%
—
—
—
—
cases:6.37%
controls:0.95%
cases:13.20%
controls:3.31%
13
58
371
3769
13
37
371
3790
6
5
378
3822
—
—
24
36
353
3745
45
113
296
3304
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
1.0e+00
1.2e+00
2.1e+00
—
1.2e+00
1.6e+00
1.3e+00
cases:16.67%
controls:6.79%
cases:10.94%
controls:3.71%
cases:4.95%
controls:0.63%
—
—
cases:1.83%
controls:0.55%
cases:14.85%
controls:3.49%
cases:29.91%
controls:10.21%
64
260
320
3567
42
142
342
3685
19
24
365
3803
—
7
21
376
3800
56
132
321
3649
102
349
239
3068
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
7.4e-01
9.3e-01
1.6e+00
—
1.6e+00
1.1e+00
1.1e+00
cases:17.45%
controls:9.12%
cases:13.54%
controls:5.83%
cases:5.47%
controls:1.18%
—
—
cases:3.92%
controls:0.79%
cases:16.45%
controls:5.95%
cases:31.67%
controls:13.87%
67
349
317
3478
52
223
332
3604
21
45
363
3782
—
15
30
368
3791
62
225
315
3556
108
474
233
2943
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
7.9e-01
1.1e+00
2.5e+00
—
—
1.6e+00
1.2e+00
cases:4.17%
controls:1.93%
cases:3.91%
controls:1.28%
cases:1.82%
controls:0.16%
—
—
—
—
cases:6.90%
controls:1.43%
cases:14.96%
controls:5.18%
16
74
368
3753
15
49
369
3778
7
6
377
3821
—
—
26
54
351
3727
51
177
290
3240
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
6.5e-01
1.1e+00
1.6e+00
—
1.1e+00
1.1e+00
7.9e-01
cases:21.35%
controls:12.39%
cases:23.70%
controls:8.96%
cases:8.33%
controls:1.80%
—
—
cases:4.44%
controls:1.57%
cases:23.08%
controls:9.18%
cases:39.00%
controls:22.56%
82
474
302
3353
91
343
293
3484
32
69
352
3758
—
17
60
366
3761
87
347
290
3434
133
771
208
2646
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
8.0e-01
1.1e+00
2.0e+00
—
—
9.1e-01
1.3e+00
cases:8.07%
controls:3.79%
cases:5.99%
controls:2.06%
cases:2.34%
controls:0.31%
—
—
—
—
cases:6.10%
controls:2.54%
cases:20.23%
controls:6.32%
31
145
353
3682
23
79
361
3748
9
12
375
3815
—
—
23
96
354
3685
69
216
272
3201
Medical doctor
Z2221 [2001311556]
1.1e+00
1.3e+00
—
1.0e+50
—
1.9e+00
1.9e+00
cases:7.29%
controls:2.59%
cases:3.13%
controls:0.86%
—
—
cases:2.08%
controls:0.00%
—
—
cases:4.51%
controls:0.71%
cases:8.80%
controls:1.46%
28
99
356
3728
12
33
372
3794
—
8
0
376
3827
—
17
27
360
3754
30
50
311
3367
pH of Urine
2756-5 [3015736]
5.6e-01
9.7e-01
2.4e+00
—
—
1.4e+00
1.0e+00
cases:5.99%
controls:3.50%
cases:4.95%
controls:1.93%
cases:2.34%
controls:0.21%
—
—
—
—
cases:7.69%
controls:1.96%
cases:17.01%
controls:6.94%
23
134
361
3693
19
74
365
3753
9
8
375
3819
—
—
29
74
348
3707
58
237
283
3180
Hepatitis B virus core and surface Ab and surface Ag panel - Serum
77190-7 [46237023]
1.6e+00
—
—
—
—
2.2e+00
1.9e+00
cases:2.86%
controls:0.57%
—
—
—
—
—
—
—
—
cases:1.86%
controls:0.21%
cases:3.52%
controls:0.56%
11
22
373
3805
—
—
—
—
7
8
370
3773
12
19
329
3398
Kolposcopy
ULA02 [2001306679]
3.1e+00
—
—
1.0e+50
—
—
2.5e+00
cases:2.86%
controls:0.13%
—
—
—
—
cases:4.69%
controls:0.00%
—
—
—
—
cases:3.52%
controls:0.29%
11
5
373
3822
—
—
18
0
366
3827
—
—
12
10
329
3407
Case Management Agency
251B00000X [38004193]
-1.1e-02
2.0e-01
1.1e+00
3.8e+00
4.6e-01
2.7e-01
1.2e-01
cases:46.61%
controls:46.88%
cases:42.97%
controls:38.15%
cases:33.07%
controls:13.80%
cases:27.08%
controls:0.81%
cases:20.10%
controls:13.77%
cases:47.48%
controls:40.81%
cases:65.10%
controls:62.31%
179
1794
205
2033
165
1460
219
2367
127
528
257
3299
104
31
280
3796
77
526
306
3295
179
1543
198
2238
222
2129
119
1288
azithromycin; oral, parenteral
J01FA10 [21602978]
1.0e+00
1.2e+00
2.2e+00
—
—
7.9e-01
9.3e-01
cases:19.53%
controls:8.18%
cases:7.55%
controls:2.30%
cases:2.34%
controls:0.26%
—
—
—
—
cases:5.57%
controls:2.62%
cases:17.01%
controls:7.46%
75
313
309
3514
29
88
355
3739
9
10
375
3817
—
—
21
99
356
3682
58
255
283
3162
Supplier / Service Provider
OMOP5117446 [33004]
-9.2e-01
-1.3e+00
4.4e-01
—
—
3.4e+00
3.8e+00
cases:13.54%
controls:28.25%
cases:2.60%
controls:9.25%
cases:1.82%
controls:1.18%
—
—
—
—
cases:3.98%
controls:0.13%
cases:17.60%
controls:0.47%
52
1081
332
2746
10
354
374
3473
7
45
377
3782
—
—
15
5
362
3776
60
16
281
3401
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
3.7e-01
7.7e-01
1.5e+00
—
8.4e-01
8.8e-01
4.7e-01
cases:25.52%
controls:19.10%
cases:23.44%
controls:12.46%
cases:10.16%
controls:2.43%
—
—
cases:5.74%
controls:2.56%
cases:27.32%
controls:13.46%
cases:39.30%
controls:28.77%
98
731
286
3096
90
477
294
3350
39
93
345
3734
—
22
98
361
3723
103
509
274
3272
134
983
207
2434
CD3+CD4+ (T4 helper) cells/cells in Blood
8123-2 [3014037]
—
1.0e+50
1.0e+50
—
—
—
4.4e+00
—
—
cases:3.13%
controls:0.00%
cases:1.30%
controls:0.00%
—
—
—
—
—
—
cases:12.90%
controls:0.18%
—
12
0
372
3827
5
0
379
3827
—
—
—
44
6
297
3411
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
5.6e-01
8.7e-01
1.4e+00
—
8.0e-01
9.9e-01
6.2e-01
cases:23.18%
controls:14.69%
cases:21.88%
controls:10.50%
cases:8.85%
controls:2.38%
—
—
cases:5.22%
controls:2.41%
cases:24.14%
controls:10.55%
cases:36.66%
controls:23.73%
89
562
295
3265
84
402
300
3425
34
91
350
3736
—
20
92
363
3729
91
399
286
3382
125
811
216
2606
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
2.5e+00
—
—
—
—
2.1e+00
1.8e+00
cases:1.82%
controls:0.16%
—
—
—
—
—
—
—
—
cases:1.33%
controls:0.16%
cases:3.52%
controls:0.59%
7
6
377
3821
—
—
—
—
5
6
372
3775
12
20
329
3397
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
1.3e+00
1.1e+00
—
—
-1.0e+50
1.5e+00
1.4e+00
cases:2.86%
controls:0.81%
cases:1.82%
controls:0.63%
—
—
—
—
cases:0.00%
controls:0.13%
cases:2.39%
controls:0.56%
cases:7.04%
controls:1.76%
11
31
373
3796
7
24
377
3803
—
—
0
5
383
3816
9
21
368
3760
24
60
317
3357
Obstetrics / Gynecology
16 [38004461]
4.4e-01
1.1e+00
1.9e+00
—
1.5e+00
1.0e+00
3.6e-01
cases:11.20%
controls:7.50%
cases:8.85%
controls:3.03%
cases:3.13%
controls:0.47%
—
—
cases:2.09%
controls:0.47%
cases:7.69%
controls:2.88%
cases:11.14%
controls:8.08%
43
287
341
3540
34
116
350
3711
12
18
372
3809
—
8
18
375
3803
29
109
348
3672
38
276
303
3141
Shigella sp [Presence] in Stool by Culture
82300-5 [42529406]
2.0e+00
—
—
—
—
—
2.1e+00
cases:2.60%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:2.35%
controls:0.29%
10
14
374
3813
—
—
—
—
—
8
10
333
3407
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
4.8e-01
7.5e-01
2.1e+00
—
—
1.1e+00
7.9e-01
cases:5.99%
controls:3.79%
cases:4.69%
controls:2.27%
cases:2.60%
controls:0.34%
—
—
—
—
cases:7.43%
controls:2.54%
cases:16.42%
controls:8.19%
23
145
361
3682
18
87
366
3740
10
13
374
3814
—
—
28
96
349
3685
56
280
285
3137
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
4.6e-01
7.1e-01
2.1e+00
—
—
1.1e+00
8.1e-01
cases:5.99%
controls:3.87%
cases:4.69%
controls:2.35%
cases:2.60%
controls:0.34%
—
—
—
—
cases:7.43%
controls:2.62%
cases:16.72%
controls:8.22%
23
148
361
3679
18
90
366
3737
10
13
374
3814
—
—
28
99
349
3682
57
281
284
3136
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
4.7e-01
7.5e-01
2.1e+00
—
—
1.1e+00
7.9e-01
cases:5.99%
controls:3.84%
cases:4.69%
controls:2.27%
cases:2.60%
controls:0.34%
—
—
—
—
cases:7.43%
controls:2.62%
cases:16.42%
controls:8.19%
23
147
361
3680
18
87
366
3740
10
13
374
3814
—
—
28
99
349
3682
56
280
285
3137
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.9e-01
8.2e-01
1.6e+00
—
8.2e-01
9.6e-01
4.9e-01
cases:26.56%
controls:19.62%
cases:27.34%
controls:14.16%
cases:11.72%
controls:2.51%
—
—
cases:5.48%
controls:2.49%
cases:30.77%
controls:14.52%
cases:43.99%
controls:32.43%
102
751
282
3076
105
542
279
3285
45
96
339
3731
—
21
95
362
3726
116
549
261
3232
150
1108
191
2309
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.5e-01
6.4e-01
1.5e+00
—
9.9e-01
8.2e-01
3.7e-01
cases:23.18%
controls:19.05%
cases:22.66%
controls:13.40%
cases:9.90%
controls:2.48%
—
—
cases:5.22%
controls:2.02%
cases:27.06%
controls:14.02%
cases:40.76%
controls:32.19%
89
729
295
3098
87
513
297
3314
38
95
346
3732
—
20
77
363
3744
102
530
275
3251
139
1100
202
2317
Person consulting for explanation of investigation findings
Z71.2 [45552100]
1.4e+00
6.3e-01
—
—
—
1.5e+00
9.1e-01
cases:6.77%
controls:1.70%
cases:1.56%
controls:0.84%
—
—
—
—
—
—
cases:2.39%
controls:0.56%
cases:7.33%
controls:3.07%
26
65
358
3762
6
32
378
3795
—
—
—
9
21
368
3760
25
105
316
3312
cefalexin; oral
J01DB01 [21602870]
5.8e-01
6.9e-01
1.9e+00
—
—
2.7e-01
6.1e-01
cases:35.94%
controls:23.99%
cases:14.32%
controls:7.71%
cases:6.25%
controls:0.94%
—
—
—
—
cases:10.08%
controls:7.86%
cases:38.12%
controls:25.11%
138
918
246
2909
55
295
329
3532
24
36
360
3791
—
—
38
297
339
3484
130
858
211
2559
CD4 cells/Lymphocytes in Specimen
80223-1 [21494815]
3.8e+00
1.0e+50
1.0e+50
—
—
—
—
cases:5.47%
controls:0.13%
cases:3.65%
controls:0.00%
cases:1.56%
controls:0.00%
—
—
—
—
—
—
—
—
21
5
363
3822
14
0
370
3827
6
0
378
3827
—
—
—
—
Bacteria [Presence] in Urine
87829-8 [36304419]
1.2e+00
4.9e-01
—
—
—
1.3e+00
1.3e+00
cases:6.25%
controls:1.91%
cases:2.08%
controls:1.28%
—
—
—
—
—
—
cases:3.71%
controls:1.08%
cases:9.68%
controls:2.87%
24
73
360
3754
8
49
376
3778
—
—
—
14
41
363
3740
33
98
308
3319
Hepatitis B virus surface Ab [Units/volume] in Serum
16935-9 [3023421]
1.6e+00
—
—
—
—
1.8e+00
2.2e+00
cases:2.60%
controls:0.55%
—
—
—
—
—
—
—
—
cases:1.59%
controls:0.26%
cases:3.81%
controls:0.44%
10
21
374
3806
—
—
—
—
6
10
371
3771
13
15
328
3402
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
6.9e-01
8.3e-01
—
—
—
1.2e+00
1.0e+00
cases:10.68%
controls:5.67%
cases:5.73%
controls:2.59%
—
—
—
—
—
—
cases:9.55%
controls:3.09%
cases:23.46%
controls:9.89%
41
217
343
3610
22
99
362
3728
—
—
—
36
117
341
3664
80
338
261
3079
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.0e+00
1.3e+00
—
—
—
1.3e+00
1.3e+00
cases:9.64%
controls:3.66%
cases:4.43%
controls:1.20%
—
—
—
—
—
—
cases:2.65%
controls:0.71%
cases:12.90%
controls:3.75%
37
140
347
3687
17
46
367
3781
—
—
—
10
27
367
3754
44
128
297
3289
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
1.2e+00
4.3e-01
—
—
—
1.3e+00
1.2e+00
cases:6.25%
controls:1.93%
cases:2.08%
controls:1.36%
—
—
—
—
—
—
cases:3.71%
controls:1.08%
cases:9.97%
controls:3.22%
24
74
360
3753
8
52
376
3775
—
—
—
14
41
363
3740
34
110
307
3307
Pharmacy visit
OMOP4822462 [581458]
4.3e-01
4.7e-01
9.7e-01
1.4e+00
2.6e-01
6.9e-01
7.4e-01
cases:90.36%
controls:85.92%
cases:78.91%
controls:70.05%
cases:50.00%
controls:27.52%
cases:5.47%
controls:1.36%
cases:33.68%
controls:28.06%
cases:83.02%
controls:70.99%
cases:95.31%
controls:90.64%
347
3288
37
539
303
2681
81
1146
192
1053
192
2774
21
52
363
3775
129
1072
254
2749
313
2684
64
1097
325
3097
16
320
Telehealth
OMOP5556618 [722455]
5.7e-01
3.9e-01
2.2e+00
—
8.3e-01
7.6e-01
5.0e-01
cases:22.14%
controls:13.80%
cases:6.51%
controls:4.52%
cases:4.17%
controls:0.47%
—
—
cases:1.31%
controls:0.58%
cases:8.22%
controls:4.02%
cases:18.18%
controls:11.91%
85
528
299
3299
25
173
359
3654
16
18
368
3809
—
5
22
378
3799
31
152
346
3629
62
407
279
3010
Diarrhoea
D11 [2002000310]
1.8e+00
1.7e+00
—
—
—
1.7e+00
1.7e+00
cases:5.47%
controls:0.94%
cases:1.56%
controls:0.29%
—
—
—
—
—
—
cases:1.86%
controls:0.34%
cases:6.16%
controls:1.14%
21
36
363
3791
6
11
378
3816
—
—
—
7
13
370
3768
21
39
320
3378
Immunization
WW200 [2001310599]
3.5e+00
—
—
—
—
—
—
cases:8.33%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
32
10
352
3817
—
—
—
—
—
—
fluconazole; oral, parenteral
J02AC01 [21603080]
4.5e-01
1.2e+00
2.3e+00
—
1.8e+00
1.0e+00
3.9e-01
cases:5.99%
controls:3.92%
cases:3.13%
controls:0.94%
cases:1.82%
controls:0.18%
—
—
cases:1.31%
controls:0.21%
cases:3.18%
controls:1.19%
cases:5.87%
controls:4.04%
23
150
361
3677
12
36
372
3791
7
7
377
3820
—
5
8
378
3813
12
45
365
3736
20
138
321
3279
hydrocortisone
S02BA01 [21605166]
1.6e-01
5.7e-01
2.5e+00
—
-1.0e+50
9.8e-01
4.4e-01
cases:6.25%
controls:5.38%
cases:2.60%
controls:1.49%
cases:1.56%
controls:0.13%
—
—
cases:0.00%
controls:0.18%
cases:4.24%
controls:1.64%
cases:6.74%
controls:4.45%
24
206
360
3621
10
57
374
3770
6
5
378
3822
—
0
7
383
3814
16
62
361
3719
23
152
318
3265
Abdominal pain/cramps general
D01 [2002000300]
1.4e+00
2.0e+00
—
—
—
—
1.2e+00
cases:2.60%
controls:0.63%
cases:1.56%
controls:0.21%
—
—
—
—
—
—
—
—
cases:2.05%
controls:0.61%
10
24
374
3803
6
8
378
3819
—
—
—
—
7
21
334
3396
Extensive body CT
JN4BD [2001310899]
1.7e+00
—
—
—
—
—
1.8e+00
cases:2.34%
controls:0.44%
—
—
—
—
—
—
—
—
—
—
cases:2.05%
controls:0.35%
9
17
375
3810
—
—
—
—
—
7
12
334
3405
hydrocortisone buteprate
D07AB11 [21602115]
3.9e-01
6.1e-01
2.5e+00
—
-1.0e+50
9.6e-01
3.6e-01
cases:8.59%
controls:5.96%
cases:3.13%
controls:1.72%
cases:1.56%
controls:0.13%
—
—
cases:0.00%
controls:0.26%
cases:4.77%
controls:1.88%
cases:7.33%
controls:5.24%
33
228
351
3599
12
66
372
3761
6
5
378
3822
—
0
10
383
3811
18
71
359
3710
25
179
316
3238
hydrocortisone aceponate
D07AC16 [21602135]
3.9e-01
6.1e-01
2.5e+00
—
-1.0e+50
9.6e-01
3.6e-01
cases:8.59%
controls:5.96%
cases:3.13%
controls:1.72%
cases:1.56%
controls:0.13%
—
—
cases:0.00%
controls:0.26%
cases:4.77%
controls:1.88%
cases:7.33%
controls:5.24%
33
228
351
3599
12
66
372
3761
6
5
378
3822
—
0
10
383
3811
18
71
359
3710
25
179
316
3238
hydrocortisone
D07AA02 [21602102]
3.9e-01
6.1e-01
2.5e+00
—
-1.0e+50
9.6e-01
3.6e-01
cases:8.59%
controls:5.96%
cases:3.13%
controls:1.72%
cases:1.56%
controls:0.13%
—
—
cases:0.00%
controls:0.26%
cases:4.77%
controls:1.88%
cases:7.33%
controls:5.24%
33
228
351
3599
12
66
372
3761
6
5
378
3822
—
0
10
383
3811
18
71
359
3710
25
179
316
3238
hydrocortisone butyrate
D07AB02 [21602106]
3.9e-01
6.1e-01
2.5e+00
—
-1.0e+50
9.6e-01
3.6e-01
cases:8.59%
controls:5.96%
cases:3.13%
controls:1.72%
cases:1.56%
controls:0.13%
—
—
cases:0.00%
controls:0.26%
cases:4.77%
controls:1.88%
cases:7.33%
controls:5.24%
33
228
351
3599
12
66
372
3761
6
5
378
3822
—
0
10
383
3811
18
71
359
3710
25
179
316
3238
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
2.4e-01
6.4e-01
1.6e+00
—
7.0e-01
6.6e-01
5.0e-01
cases:17.45%
controls:14.21%
cases:13.54%
controls:7.63%
cases:4.43%
controls:0.89%
—
—
cases:1.57%
controls:0.79%
cases:14.32%
controls:7.96%
cases:32.84%
controls:22.94%
67
544
317
3283
52
292
332
3535
17
34
367
3793
—
6
30
377
3791
54
301
323
3480
112
784
229
2633
hydrocortisone
A07EA02 [21600654]
3.7e-01
6.8e-01
2.5e+00
—
-1.0e+50
9.3e-01
3.5e-01
cases:8.59%
controls:6.11%
cases:3.39%
controls:1.75%
cases:1.56%
controls:0.13%
—
—
cases:0.00%
controls:0.26%
cases:4.77%
controls:1.93%
cases:7.33%
controls:5.27%
33
234
351
3593
13
67
371
3760
6
5
378
3822
—
0
10
383
3811
18
73
359
3708
25
180
316
3237
hydrocortisone
C05AA01 [21601608]
3.7e-01
6.8e-01
2.5e+00
—
-1.0e+50
9.3e-01
3.5e-01
cases:8.59%
controls:6.11%
cases:3.39%
controls:1.75%
cases:1.56%
controls:0.13%
—
—
cases:0.00%
controls:0.26%
cases:4.77%
controls:1.93%
cases:7.33%
controls:5.27%
33
234
351
3593
13
67
371
3760
6
5
378
3822
—
0
10
383
3811
18
73
359
3708
25
180
316
3237
Anogenital (venereal) warts
A63.0 [45585929]
—
—
—
—
—
—
3.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.40%
controls:0.18%
—
—
—
—
—
—
15
6
326
3411
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
1.7e+00
—
—
—
—
—
1.5e+00
cases:3.91%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:2.93%
controls:0.67%
15
27
369
3800
—
—
—
—
—
10
23
331
3394
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
1.1e+00
4.4e-01
—
—
—
1.1e+00
1.0e+00
cases:6.51%
controls:2.25%
cases:2.34%
controls:1.52%
—
—
—
—
—
—
cases:3.71%
controls:1.30%
cases:9.68%
controls:3.63%
25
86
359
3741
9
58
375
3769
—
—
—
14
49
363
3732
33
124
308
3293
valaciclovir; oral
J05AB11 [21603137]
1.4e+00
—
—
—
—
7.9e-01
1.8e+00
cases:3.39%
controls:0.86%
—
—
—
—
—
—
—
—
cases:1.33%
controls:0.61%
cases:7.04%
controls:1.23%
13
33
371
3794
—
—
—
—
5
23
372
3758
24
42
317
3375
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
1.1e+00
1.2e-01
—
—
—
1.0e+00
9.3e-01
cases:7.03%
controls:2.40%
cases:1.82%
controls:1.62%
—
—
—
—
—
—
cases:3.98%
controls:1.45%
cases:9.97%
controls:4.18%
27
92
357
3735
7
62
377
3765
—
—
—
15
55
362
3726
34
143
307
3274
Abnormal findings in specimens from female genital organs, abnormal cytological findings
R87.6 [45558487]
2.9e+00
—
—
—
—
—
1.6e+00
cases:3.39%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.29%
13
7
371
3820
—
—
—
—
—
5
10
336
3407
zopiclone; oral
N05CF01 [21604654]
8.7e-01
1.0e+00
1.4e+00
—
—
7.2e-01
9.7e-01
cases:7.55%
controls:3.32%
cases:4.69%
controls:1.72%
cases:1.82%
controls:0.47%
—
—
—
—
cases:4.24%
controls:2.12%
cases:11.44%
controls:4.65%
29
127
355
3700
18
66
366
3761
7
18
377
3809
—
—
16
80
361
3701
39
159
302
3258
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
1.4e+00
1.4e+00
—
—
—
1.3e+00
1.4e+00
cases:3.13%
controls:0.81%
cases:2.34%
controls:0.57%
—
—
—
—
—
—
cases:2.39%
controls:0.63%
cases:4.40%
controls:1.08%
12
31
372
3796
9
22
375
3805
—
—
—
9
24
368
3757
15
37
326
3380
Hepatitis A virus Ab [Presence] in Serum
20575-7 [3016650]
2.0e+00
—
—
—
—
—
2.8e+00
cases:1.30%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
cases:4.11%
controls:0.26%
5
7
379
3820
—
—
—
—
—
14
9
327
3408
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
3.9e-01
6.3e-01
1.5e+00
—
8.5e-01
5.8e-01
4.0e-01
cases:23.96%
controls:17.59%
cases:17.45%
controls:10.09%
cases:8.59%
controls:1.96%
—
—
cases:4.18%
controls:1.83%
cases:16.71%
controls:10.10%
cases:33.14%
controls:24.99%
92
673
292
3154
67
386
317
3441
33
75
351
3752
—
16
70
367
3751
63
382
314
3399
113
854
228
2563
combinations of corticosteroids
D07XB30 [21602188]
3.8e-01
4.9e-01
2.0e+00
—
—
7.1e-01
7.2e-01
cases:11.72%
controls:8.34%
cases:4.69%
controls:2.93%
cases:2.60%
controls:0.37%
—
—
—
—
cases:6.37%
controls:3.23%
cases:16.72%
controls:8.93%
45
319
339
3508
18
112
366
3715
10
14
374
3813
—
—
24
122
353
3659
57
305
284
3112
combinations of corticosteroids
D07AB30 [21602118]
3.8e-01
4.9e-01
2.0e+00
—
—
7.1e-01
7.2e-01
cases:11.72%
controls:8.34%
cases:4.69%
controls:2.93%
cases:2.60%
controls:0.37%
—
—
—
—
cases:6.37%
controls:3.23%
cases:16.72%
controls:8.93%
45
319
339
3508
18
112
366
3715
10
14
374
3813
—
—
24
122
353
3659
57
305
284
3112
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.4e-01
6.7e-01
1.3e+00
—
6.4e-01
7.1e-01
2.6e-01
cases:28.13%
controls:23.60%
cases:28.65%
controls:17.09%
cases:11.98%
controls:3.55%
—
—
cases:6.53%
controls:3.56%
cases:30.50%
controls:17.77%
cases:43.40%
controls:37.25%
108
903
276
2924
110
654
274
3173
46
136
338
3691
—
25
136
358
3685
115
672
262
3109
148
1273
193
2144
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.4e-01
6.7e-01
1.3e+00
—
6.5e-01
7.0e-01
2.6e-01
cases:28.13%
controls:23.60%
cases:28.65%
controls:17.04%
cases:11.98%
controls:3.55%
—
—
cases:6.53%
controls:3.51%
cases:30.24%
controls:17.75%
cases:43.40%
controls:37.17%
108
903
276
2924
110
652
274
3175
46
136
338
3691
—
25
134
358
3687
114
671
263
3110
148
1270
193
2147
MCH [Entitic mass]
28539-5 [3035941]
2.4e-01
6.7e-01
1.3e+00
—
6.5e-01
7.0e-01
2.6e-01
cases:28.13%
controls:23.54%
cases:28.65%
controls:17.06%
cases:11.98%
controls:3.55%
—
—
cases:6.53%
controls:3.53%
cases:30.24%
controls:17.75%
cases:43.40%
controls:37.23%
108
901
276
2926
110
653
274
3174
46
136
338
3691
—
25
135
358
3686
114
671
263
3110
148
1272
193
2145
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.5e-01
6.8e-01
1.3e+00
—
6.4e-01
6.9e-01
2.5e-01
cases:28.39%
controls:23.62%
cases:28.91%
controls:17.06%
cases:11.98%
controls:3.58%
—
—
cases:6.53%
controls:3.56%
cases:30.24%
controls:17.83%
cases:43.40%
controls:37.28%
109
904
275
2923
111
653
273
3174
46
137
338
3690
—
25
136
358
3685
114
674
263
3107
148
1274
193
2143
Platelets [#/volume] in Blood
26515-7 [3007461]
2.4e-01
6.7e-01
1.3e+00
—
6.5e-01
6.9e-01
2.6e-01
cases:28.13%
controls:23.52%
cases:28.65%
controls:17.04%
cases:11.98%
controls:3.53%
—
—
cases:6.53%
controls:3.53%
cases:29.97%
controls:17.72%
cases:43.40%
controls:37.08%
108
900
276
2927
110
652
274
3175
46
135
338
3692
—
25
135
358
3686
113
670
264
3111
148
1267
193
2150
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.4e-01
6.7e-01
1.3e+00
—
6.4e-01
7.0e-01
2.6e-01
cases:28.13%
controls:23.62%
cases:28.65%
controls:17.09%
cases:11.98%
controls:3.55%
—
—
cases:6.53%
controls:3.56%
cases:30.24%
controls:17.77%
cases:43.40%
controls:37.25%
108
904
276
2923
110
654
274
3173
46
136
338
3691
—
25
136
358
3685
114
672
263
3109
148
1273
193
2144
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.3e-01
6.8e-01
1.3e+00
—
6.3e-01
6.9e-01
2.5e-01
cases:28.13%
controls:23.67%
cases:28.91%
controls:17.09%
cases:11.98%
controls:3.58%
—
—
cases:6.53%
controls:3.59%
cases:30.24%
controls:17.85%
cases:43.40%
controls:37.43%
108
906
276
2921
111
654
273
3173
46
137
338
3690
—
25
137
358
3684
114
675
263
3106
148
1279
193
2138
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
8.5e-01
6.4e-01
1.5e+00
—
—
9.8e-01
7.0e-01
cases:11.98%
controls:5.49%
cases:5.73%
controls:3.11%
cases:1.82%
controls:0.42%
—
—
—
—
cases:6.90%
controls:2.70%
cases:13.78%
controls:7.37%
46
210
338
3617
22
119
362
3708
7
16
377
3811
—
—
26
102
351
3679
47
252
294
3165
Acute pharyngitis, unspecified
J02.9 [45538472]
—
2.5e+00
—
—
—
—
—
—
—
cases:1.56%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
6
5
378
3822
—
—
—
—
—
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
2.1e-01
6.2e-01
1.3e+00
—
8.0e-01
5.3e-01
3.4e-01
cases:19.27%
controls:16.20%
cases:16.15%
controls:9.41%
cases:4.17%
controls:1.12%
—
—
cases:2.35%
controls:1.07%
cases:16.98%
controls:10.76%
cases:35.78%
controls:28.45%
74
620
310
3207
62
360
322
3467
16
43
368
3784
—
9
41
374
3780
64
407
313
3374
122
972
219
2445
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
2.1e-01
6.2e-01
1.3e+00
—
7.0e-01
5.2e-01
3.2e-01
cases:19.53%
controls:16.46%
cases:16.41%
controls:9.51%
cases:4.17%
controls:1.18%
—
—
cases:2.35%
controls:1.18%
cases:17.24%
controls:11.00%
cases:35.78%
controls:28.86%
75
630
309
3197
63
364
321
3463
16
45
368
3782
—
9
45
374
3776
65
416
312
3365
122
986
219
2431
aciclovir; oral, parenteral
J05AB01 [21603131]
1.0e+00
1.3e+00
—
—
—
9.8e-01
1.4e+00
cases:3.91%
controls:1.44%
cases:2.60%
controls:0.71%
—
—
—
—
—
—
cases:1.33%
controls:0.50%
cases:6.74%
controls:1.79%
15
55
369
3772
10
27
374
3800
—
—
—
5
19
372
3762
23
61
318
3356
doxycycline; oral, parenteral
J01AA02 [21602800]
7.6e-01
5.6e-01
1.6e+00
—
9.2e-01
8.5e-01
7.9e-01
cases:26.56%
controls:14.50%
cases:8.07%
controls:4.78%
cases:2.08%
controls:0.44%
—
—
cases:1.57%
controls:0.63%
cases:10.34%
controls:4.68%
cases:26.69%
controls:14.19%
102
555
282
3272
31
183
353
3644
8
17
376
3810
—
6
24
377
3797
39
177
338
3604
91
485
250
2932
alprostadil; implant, parenteral
G04BE01 [21602646]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.35%
controls:0.23%
—
—
—
—
—
—
8
8
333
3409
alprostadil; parenteral
C01EA01 [21600362]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.05%
controls:0.20%
—
—
—
—
—
—
7
7
334
3410
Sytologyspecimen from mouth of uterus
XLD00 [2001306651]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.76%
controls:0.18%
—
—
—
—
—
—
6
6
335
3411
Allergy, unspecified
T78.4 [45580373]
2.3e+00
—
—
—
—
—
—
cases:1.56%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
378
3821
—
—
—
—
—
—
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
3.2e-01
4.2e-01
1.3e+00
—
6.4e-01
5.7e-01
4.3e-01
cases:15.63%
controls:11.89%
cases:11.98%
controls:8.20%
cases:4.17%
controls:1.18%
—
—
cases:1.83%
controls:0.97%
cases:14.32%
controls:8.67%
cases:32.84%
controls:24.06%
60
455
324
3372
46
314
338
3513
16
45
368
3782
—
7
37
376
3784
54
328
323
3453
112
822
229
2595
Deposits [accretions] on teeth betel
K03.65 [2000502690]
1.0e+00
8.9e-01
—
—
—
1.0e+00
1.1e+00
cases:5.21%
controls:1.91%
cases:1.82%
controls:0.76%
—
—
—
—
—
—
cases:2.39%
controls:0.87%
cases:7.62%
controls:2.60%
20
73
364
3754
7
29
377
3798
—
—
—
9
33
368
3748
26
89
315
3328
Gliadin peptide IgA Ab [Units/volume] in Serum by Immunoassay
63453-5 [40766183]
2.2e+00
—
—
—
—
—
—
cases:1.56%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
378
3820
—
—
—
—
—
—
Hepatitis A virus IgM Ab [Presence] in Serum
22314-9 [3013327]
2.2e+00
—
—
—
—
—
—
cases:1.56%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
378
3820
—
—
—
—
—
—
terbinafine; oral
D01BA02 [21601967]
8.3e-01
3.9e-01
—
—
—
1.3e+00
6.0e-01
cases:6.51%
controls:2.95%
cases:1.30%
controls:0.89%
—
—
—
—
—
—
cases:3.45%
controls:0.95%
cases:5.87%
controls:3.31%
25
113
359
3714
5
34
379
3793
—
—
—
13
36
364
3745
20
113
321
3304
Lumbar puncture
TAB00 [2001300538]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.64%
controls:0.32%
—
—
—
—
—
—
9
11
332
3406
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
8.8e-01
—
—
—
—
2.0e+00
2.1e+00
cases:1.56%
controls:0.65%
—
—
—
—
—
—
—
—
cases:1.33%
controls:0.19%
cases:2.05%
controls:0.26%
6
25
378
3802
—
—
—
—
5
7
372
3774
7
9
334
3408
finasteride; oral
D11AX10 [21602350]
—
—
—
—
—
2.0e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:2.39%
controls:0.32%
cases:2.64%
controls:0.73%
—
—
—
—
—
9
12
368
3769
9
25
332
3392
finasteride; oral
G04CB01 [21602675]
—
—
—
—
—
2.0e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:2.39%
controls:0.32%
cases:2.64%
controls:0.73%
—
—
—
—
—
9
12
368
3769
9
25
332
3392
Persons encountering health services in other circumstances
Z76 [45537674]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.76%
controls:0.23%
—
—
—
—
—
—
6
8
335
3409
ofloxacin
S01AE01 [43534856]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.76%
controls:0.23%
—
—
—
—
—
—
6
8
335
3409
aciclovir
D06BB03 [21602085]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.76%
controls:0.23%
—
—
—
—
—
—
6
8
335
3409
Pain in throat
R07.0 [45592406]
2.0e+00
—
—
—
—
—
5.9e-01
cases:2.34%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.82%
9
12
375
3815
—
—
—
—
—
5
28
336
3389
Outpatient Hospital
22 [8756]
8.5e-02
1.0e-01
1.3e+00
—
2.0e+00
4.1e-01
2.2e-01
cases:16.15%
controls:15.02%
cases:4.43%
controls:4.02%
cases:2.08%
controls:0.55%
—
—
cases:3.66%
controls:0.50%
cases:5.84%
controls:3.97%
cases:16.72%
controls:13.81%
62
575
322
3252
17
154
367
3673
8
21
376
3806
—
14
19
369
3802
22
150
355
3631
57
472
284
2945
Anoscopy
UJH02 [2001305182]
2.0e+00
—
—
—
—
—
—
cases:1.56%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
378
3819
—
—
—
—
—
—
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
2.0e+00
—
—
—
—
—
1.3e+00
cases:1.56%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
cases:2.35%
controls:0.64%
6
8
378
3819
—
—
—
—
—
8
22
333
3395
Urinary frequency/urgency
U02 [2002001138]
—
—
—
—
—
-1.0e+50
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:2.35%
controls:0.32%
—
—
—
—
—
0
6
377
3775
8
11
333
3406
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
—
-1.0e+50
—
—
—
—
2.0e+00
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
cases:2.35%
controls:0.32%
—
0
5
384
3822
—
—
—
—
8
11
333
3406
Fungus identified in Specimen by Culture
580-1 [3000494]
7.9e-01
—
—
—
—
2.0e+00
5.4e-01
cases:1.82%
controls:0.84%
—
—
—
—
—
—
—
—
cases:2.12%
controls:0.29%
cases:2.93%
controls:1.73%
7
32
377
3795
—
—
—
—
8
11
369
3770
10
59
331
3358
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
3.8e-01
1.3e+00
—
—
—
9.2e-01
7.5e-01
cases:1.82%
controls:1.25%
cases:3.13%
controls:0.91%
—
—
—
—
—
—
cases:3.71%
controls:1.51%
cases:13.20%
controls:6.73%
7
48
377
3779
12
35
372
3792
—
—
—
14
57
363
3724
45
230
296
3187
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
2.0e+00
—
—
—
—
—
1.6e+00
cases:2.60%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.29%
10
14
374
3813
—
—
—
—
—
5
10
336
3407
Yersinia sp identified in Stool by Organism specific culture
28549-4 [3014765]
2.0e+00
—
—
—
—
—
1.5e+00
cases:2.60%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.32%
10
14
374
3813
—
—
—
—
—
5
11
336
3406
oxazepam; oral
N05BA04 [21604569]
7.1e-01
9.7e-01
1.1e+00
—
—
1.1e+00
8.8e-01
cases:5.73%
controls:2.90%
cases:3.39%
controls:1.31%
cases:1.30%
controls:0.44%
—
—
—
—
cases:4.51%
controls:1.56%
cases:8.50%
controls:3.72%
22
111
362
3716
13
50
371
3777
5
17
379
3810
—
—
17
59
360
3722
29
127
312
3290
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
2.1e-01
5.3e-01
1.4e+00
—
6.8e-01
4.6e-01
3.0e-01
cases:19.53%
controls:16.41%
cases:16.15%
controls:10.16%
cases:4.69%
controls:1.18%
—
—
cases:2.35%
controls:1.20%
cases:16.98%
controls:11.48%
cases:36.07%
controls:29.56%
75
628
309
3199
62
389
322
3438
18
45
366
3782
—
9
46
374
3775
64
434
313
3347
123
1010
218
2407
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
7.7e-01
1.1e+00
—
—
—
4.3e-01
5.6e-01
cases:7.03%
controls:3.37%
cases:3.91%
controls:1.28%
—
—
—
—
—
—
cases:1.86%
controls:1.22%
cases:6.45%
controls:3.78%
27
129
357
3698
15
49
369
3778
—
—
—
7
46
370
3735
22
129
319
3288
Contact with and exposure to infections with a predominantly sexual mode of transmission
Z20.2 [45609914]
—
—
1.0e+50
—
—
—
1.9e+00
—
—
—
—
cases:1.30%
controls:0.00%
—
—
—
—
—
—
cases:2.05%
controls:0.32%
—
—
5
0
379
3827
—
—
—
7
11
334
3406
hydrocortisone; local oral
A01AC03 [21600036]
3.0e-01
—
—
—
—
1.9e+00
3.6e-01
cases:1.30%
controls:0.97%
—
—
—
—
—
—
—
—
cases:1.86%
controls:0.29%
cases:1.47%
controls:1.02%
5
37
379
3790
—
—
—
—
7
11
370
3770
5
35
336
3382
Fever
A03 [2002000144]
9.2e-01
8.7e-01
—
—
—
1.8e+00
5.6e-01
cases:3.91%
controls:1.59%
cases:1.30%
controls:0.55%
—
—
—
—
—
—
cases:2.12%
controls:0.34%
cases:3.23%
controls:1.87%
15
61
369
3766
5
21
379
3806
—
—
—
8
13
369
3768
11
64
330
3353
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
1.8e+00
—
—
—
—
—
1.3e+00
cases:2.08%
controls:0.34%
—
—
—
—
—
—
—
—
—
—
cases:1.76%
controls:0.50%
8
13
376
3814
—
—
—
—
—
6
17
335
3400
androstanolone
G03BB02 [21602513]
1.3e+00
1.6e+00
—
—
—
1.3e+00
1.8e+00
cases:2.08%
controls:0.57%
cases:1.82%
controls:0.39%
—
—
—
—
—
—
cases:1.86%
controls:0.50%
cases:3.81%
controls:0.64%
8
22
376
3805
7
15
377
3812
—
—
—
7
19
370
3762
13
22
328
3395
Gastroenteritis presumed infection
D73 [2002000371]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.05%
controls:0.35%
—
—
—
—
—
—
7
12
334
3405
ibuprofen
R02AX02 [1588667]
4.0e-01
2.3e-01
9.1e-01
—
8.0e-01
4.7e-01
1.6e-01
cases:41.15%
controls:31.83%
cases:17.45%
controls:14.35%
cases:5.47%
controls:2.27%
—
—
cases:3.13%
controls:1.44%
cases:19.89%
controls:13.49%
cases:40.76%
controls:37.08%
158
1218
226
2609
67
549
317
3278
21
87
363
3740
—
12
55
371
3766
75
510
302
3271
139
1267
202
2150
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
4.0e-01
2.3e-01
9.1e-01
—
8.0e-01
4.7e-01
1.6e-01
cases:41.15%
controls:31.83%
cases:17.45%
controls:14.35%
cases:5.47%
controls:2.27%
—
—
cases:3.13%
controls:1.44%
cases:19.89%
controls:13.49%
cases:40.76%
controls:37.08%
158
1218
226
2609
67
549
317
3278
21
87
363
3740
—
12
55
371
3766
75
510
302
3271
139
1267
202
2150
oseltamivir; oral
J05AH02 [21603179]
1.8e+00
—
—
—
—
—
—
cases:1.82%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
7
12
377
3815
—
—
—
—
—
—
androstanolone
A14AA01 [21600917]
1.3e+00
1.5e+00
—
—
—
1.3e+00
1.8e+00
cases:2.08%
controls:0.57%
cases:1.82%
controls:0.42%
—
—
—
—
—
—
cases:1.86%
controls:0.50%
cases:3.81%
controls:0.67%
8
22
376
3805
7
16
377
3811
—
—
—
7
19
370
3762
13
23
328
3394
betamethasone
S03BA03 [21605203]
8.0e-01
—
—
—
-1.0e+50
1.7e+00
8.5e-01
cases:3.65%
controls:1.67%
—
—
—
—
—
—
cases:0.00%
controls:0.13%
cases:2.92%
controls:0.56%
cases:3.23%
controls:1.40%
14
64
370
3763
—
—
—
0
5
383
3816
11
21
366
3760
11
48
330
3369
Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]
1.7e+00
—
—
—
—
2.1e+00
1.9e+00
cases:2.34%
controls:0.44%
—
—
—
—
—
—
—
—
cases:1.33%
controls:0.16%
cases:1.76%
controls:0.26%
9
17
375
3810
—
—
—
—
5
6
372
3775
6
9
335
3408
Inpatient Hospital
21 [8717]
1.0e-01
-5.2e-02
1.1e+00
1.0e+50
1.7e+00
5.7e-01
2.4e-01
cases:23.44%
controls:21.69%
cases:6.25%
controls:6.56%
cases:2.86%
controls:0.97%
cases:10.16%
controls:0.00%
cases:3.92%
controls:0.76%
cases:10.88%
controls:6.43%
cases:23.17%
controls:19.20%
90
830
294
2997
24
251
360
3576
11
37
373
3790
39
0
345
3827
15
29
368
3792
41
243
336
3538
79
656
262
2761
mirtazapine; oral
N06AX11 [21604740]
7.3e-01
4.4e-01
-1.0e+50
—
—
5.9e-01
8.9e-01
cases:7.29%
controls:3.66%
cases:3.13%
controls:2.04%
cases:0.00%
controls:0.57%
—
—
—
—
cases:3.71%
controls:2.09%
cases:10.56%
controls:4.62%
28
140
356
3687
12
78
372
3749
0
22
384
3805
—
—
14
79
363
3702
36
158
305
3259
Upper respiratory infection acute
R74 [2002000942]
8.8e-01
4.1e-01
—
—
—
9.8e-01
7.0e-01
cases:8.07%
controls:3.50%
cases:2.34%
controls:1.57%
—
—
—
—
—
—
cases:3.71%
controls:1.43%
cases:11.14%
controls:5.88%
31
134
353
3693
9
60
375
3767
—
—
—
14
54
363
3727
38
201
303
3216
Radiological examination, not elsewhere classified
Z01.6 [45605096]
1.6e+00
-1.0e+50
—
—
—
—
6.6e-01
cases:2.60%
controls:0.55%
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.76%
10
21
374
3806
0
6
384
3821
—
—
—
—
5
26
336
3391
chloramphenicol
S01AA01 [21603554]
5.4e-01
8.4e-01
—
—
-1.0e+50
9.5e-01
6.3e-01
cases:8.59%
controls:5.20%
cases:4.43%
controls:1.96%
—
—
—
—
cases:0.00%
controls:0.29%
cases:5.04%
controls:2.01%
cases:13.20%
controls:7.52%
33
199
351
3628
17
75
367
3752
—
—
0
11
383
3810
19
76
358
3705
45
257
296
3160
chloramphenicol
S03AA08 [21605197]
5.4e-01
8.4e-01
—
—
-1.0e+50
9.5e-01
6.3e-01
cases:8.59%
controls:5.20%
cases:4.43%
controls:1.96%
—
—
—
—
cases:0.00%
controls:0.29%
cases:5.04%
controls:2.01%
cases:13.20%
controls:7.52%
33
199
351
3628
17
75
367
3752
—
—
0
11
383
3810
19
76
358
3705
45
257
296
3160
Dermatitis, unspecified
L30.9 [45572271]
6.2e-01
1.6e+00
—
—
—
1.4e+00
-1.1e-01
cases:2.34%
controls:1.28%
cases:2.34%
controls:0.50%
—
—
—
—
—
—
cases:2.12%
controls:0.56%
cases:2.05%
controls:2.28%
9
49
375
3778
9
19
375
3808
—
—
—
8
21
369
3760
7
78
334
3339
Throat symptom/complaint
R21 [2002000891]
7.4e-01
1.5e+00
—
—
—
—
3.6e-01
cases:4.69%
controls:2.30%
cases:2.60%
controls:0.57%
—
—
—
—
—
—
—
—
cases:3.23%
controls:2.28%
18
88
366
3739
10
22
374
3805
—
—
—
—
11
78
330
3339
Psychiatry
26 [38004469]
7.5e-01
4.6e-01
8.3e-01
—
1.0e+00
7.2e-01
7.5e-01
cases:11.72%
controls:5.91%
cases:5.21%
controls:3.34%
cases:3.13%
controls:1.38%
—
—
cases:3.13%
controls:1.18%
cases:6.63%
controls:3.33%
cases:12.32%
controls:6.20%
45
226
339
3601
20
128
364
3699
12
53
372
3774
—
12
45
371
3776
25
126
352
3655
42
212
299
3205
hydroxychloroquine; oral
P01BA02 [21604889]
—
—
-1.0e+50
—
—
9.8e-01
1.5e+00
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
cases:1.33%
controls:0.50%
cases:2.64%
controls:0.61%
—
—
0
7
384
3820
—
—
5
19
372
3762
9
21
332
3396
More than one and less than three hours
ZXE10 [2001311401]
5.7e-01
8.2e-01
—
—
—
1.5e+00
8.1e-01
cases:4.95%
controls:2.85%
cases:1.82%
controls:0.81%
—
—
—
—
—
—
cases:2.65%
controls:0.63%
cases:4.69%
controls:2.14%
19
109
365
3718
7
31
377
3796
—
—
—
10
24
367
3757
16
73
325
3344
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
3.6e-01
4.9e-01
1.4e+00
—
1.2e+00
4.9e-01
4.1e-01
cases:12.50%
controls:9.04%
cases:6.77%
controls:4.26%
cases:2.60%
controls:0.65%
—
—
cases:1.83%
controls:0.58%
cases:7.16%
controls:4.50%
cases:17.01%
controls:11.97%
48
346
336
3481
26
163
358
3664
10
25
374
3802
—
7
22
376
3799
27
170
350
3611
58
409
283
3008
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
1.0e+00
5.8e-01
—
—
-1.0e+50
1.2e+00
1.4e+00
cases:2.60%
controls:0.97%
cases:1.30%
controls:0.73%
—
—
—
—
cases:0.00%
controls:0.13%
cases:2.12%
controls:0.63%
cases:6.74%
controls:1.76%
10
37
374
3790
5
28
379
3799
—
—
0
5
383
3816
8
24
369
3757
23
60
318
3357
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
4.6e-01
7.4e-01
—
—
1.8e+00
1.1e+00
1.4e+00
cases:4.17%
controls:2.67%
cases:2.60%
controls:1.25%
—
—
—
—
cases:1.31%
controls:0.21%
cases:2.65%
controls:0.90%
cases:11.14%
controls:3.01%
16
102
368
3725
10
48
374
3779
—
—
5
8
378
3813
10
34
367
3747
38
103
303
3314
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.4e+00
—
—
—
—
—
8.2e-01
cases:3.39%
controls:0.89%
—
—
—
—
—
—
—
—
—
—
cases:2.93%
controls:1.32%
13
34
371
3793
—
—
—
—
—
10
45
331
3372
Dental examination
Z01.2 [45581002]
7.3e-01
1.4e-01
—
—
—
7.7e-01
5.9e-01
cases:9.90%
controls:5.02%
cases:2.34%
controls:2.04%
—
—
—
—
—
—
cases:4.51%
controls:2.14%
cases:13.78%
controls:8.14%
38
192
346
3635
9
78
375
3749
—
—
—
17
81
360
3700
47
278
294
3139
Upper gastrointestinal surgery
106 [44777669]
6.7e-01
5.9e-01
—
—
—
8.0e-01
6.3e-01
cases:9.38%
controls:5.02%
cases:3.91%
controls:2.19%
—
—
—
—
—
—
cases:4.24%
controls:1.96%
cases:11.44%
controls:6.44%
36
192
348
3635
15
84
369
3743
—
—
—
16
74
361
3707
39
220
302
3197
fusidic acid; ointment
D06AX01 [21602062]
5.9e-01
1.3e+00
—
—
—
7.1e-01
5.9e-01
cases:4.43%
controls:2.51%
cases:3.13%
controls:0.89%
—
—
—
—
—
—
cases:1.86%
controls:0.93%
cases:4.99%
controls:2.84%
17
96
367
3731
12
34
372
3793
—
—
—
7
35
370
3746
17
97
324
3320
fusidic acid
D09AA02 [21602265]
5.9e-01
1.3e+00
—
—
—
7.1e-01
5.9e-01
cases:4.43%
controls:2.51%
cases:3.13%
controls:0.89%
—
—
—
—
—
—
cases:1.86%
controls:0.93%
cases:4.99%
controls:2.84%
17
96
367
3731
12
34
372
3793
—
—
—
7
35
370
3746
17
97
324
3320
One hour or less
ZXE00 [2001311394]
5.9e-01
1.2e+00
—
—
—
1.3e+00
7.9e-01
cases:5.73%
controls:3.27%
cases:2.60%
controls:0.78%
—
—
—
—
—
—
cases:3.18%
controls:0.93%
cases:5.57%
controls:2.60%
22
125
362
3702
10
30
374
3797
—
—
—
12
35
365
3746
19
89
322
3328
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
2.4e-01
5.0e-01
1.3e+00
—
6.4e-01
4.8e-01
3.6e-01
cases:19.01%
controls:15.65%
cases:13.54%
controls:8.68%
cases:3.39%
controls:0.99%
—
—
cases:1.83%
controls:0.97%
cases:14.59%
controls:9.55%
cases:32.55%
controls:25.26%
73
599
311
3228
52
332
332
3495
13
38
371
3789
—
7
37
376
3784
55
361
322
3420
111
863
230
2554
Depressive episode, unspecified
F32.9 [45571760]
1.2e+00
1.4e+00
—
—
—
7.9e-01
5.6e-01
cases:4.17%
controls:1.31%
cases:2.08%
controls:0.50%
—
—
—
—
—
—
cases:1.33%
controls:0.61%
cases:2.64%
controls:1.52%
16
50
368
3777
8
19
376
3808
—
—
—
5
23
372
3758
9
52
332
3365
tadalafil; oral
G04BE08 [21602653]
9.2e-01
1.0e+00
—
—
—
1.0e+00
1.2e+00
cases:1.82%
controls:0.73%
cases:1.30%
controls:0.47%
—
—
—
—
—
—
cases:1.86%
controls:0.66%
cases:7.33%
controls:2.40%
7
28
377
3799
5
18
379
3809
—
—
—
7
25
370
3756
25
82
316
3335
fluoxetine; oral
N06AB03 [21604711]
1.1e+00
1.3e+00
-1.0e+50
—
—
1.2e+00
1.1e+00
cases:3.39%
controls:1.10%
cases:1.82%
controls:0.50%
cases:0.00%
controls:0.18%
—
—
—
—
cases:2.12%
controls:0.63%
cases:2.64%
controls:0.91%
13
42
371
3785
7
19
377
3808
0
7
384
3820
—
—
8
24
369
3757
9
31
332
3386
Dentistry
C5 [903277]
1.3e-01
-1.0e+50
—
—
—
—
1.1e+00
cases:1.30%
controls:1.15%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
cases:4.69%
controls:1.55%
5
44
379
3783
0
19
384
3808
—
—
—
—
16
53
325
3364
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.11%
controls:1.38%
—
—
—
—
—
—
14
47
327
3370
zolpidem; oral
N05CF02 [21604655]
1.1e+00
2.7e-01
—
—
—
1.0e+00
8.2e-01
cases:5.47%
controls:1.93%
cases:1.30%
controls:0.99%
—
—
—
—
—
—
cases:3.18%
controls:1.16%
cases:4.99%
controls:2.25%
21
74
363
3753
5
38
379
3789
—
—
—
12
44
365
3737
17
77
324
3340
quetiapine; oral
N05AH04 [21604544]
1.6e-01
3.2e-01
—
—
—
5.6e-01
1.1e+00
cases:3.39%
controls:2.90%
cases:2.60%
controls:1.91%
—
—
—
—
—
—
cases:3.18%
controls:1.85%
cases:9.38%
controls:3.45%
13
111
371
3716
10
73
374
3754
—
—
—
12
70
365
3711
32
118
309
3299
Pneumonia, unspecified
J18.9 [45601123]
1.1e+00
—
—
—
—
—
5.9e-01
cases:3.65%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
cases:4.11%
controls:2.31%
14
50
370
3777
—
—
—
—
—
14
79
327
3338
Nonorganic insomnia
F51.0 [45552492]
2.0e-01
—
—
—
—
—
1.0e+00
cases:1.30%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
cases:5.28%
controls:1.93%
5
41
379
3786
—
—
—
—
—
18
66
323
3351
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
1.0e+00
—
—
—
—
8.9e-01
8.7e-01
cases:4.17%
controls:1.54%
—
—
—
—
—
—
—
—
cases:1.59%
controls:0.66%
cases:4.69%
controls:2.02%
16
59
368
3768
—
—
—
—
6
25
371
3756
16
69
325
3348
CBC panel - Blood by Automated count
58410-2 [40761511]
6.3e-02
2.5e-01
1.0e+00
—
-2.7e-01
2.0e-01
2.1e-02
cases:20.31%
controls:19.31%
cases:14.32%
controls:11.50%
cases:5.47%
controls:2.09%
—
—
cases:1.57%
controls:2.04%
cases:14.06%
controls:11.85%
cases:29.91%
controls:29.47%
78
739
306
3088
55
440
329
3387
21
80
363
3747
—
6
78
377
3743
53
448
324
3333
102
1007
239
2410
Other specified counselling
Z71.8 [45581061]
8.3e-01
7.8e-01
—
—
—
1.0e+00
9.9e-01
cases:3.65%
controls:1.62%
cases:2.08%
controls:0.97%
—
—
—
—
—
—
cases:3.45%
controls:1.30%
cases:10.56%
controls:4.21%
14
62
370
3765
8
37
376
3790
—
—
—
13
49
364
3732
36
144
305
3273
Physiotherapy
R4110 [2001310233]
6.8e-01
—
—
—
—
1.1e+00
9.2e-01
cases:4.69%
controls:2.43%
—
—
—
—
—
—
—
—
cases:1.59%
controls:0.53%
cases:5.87%
controls:2.43%
18
93
366
3734
—
—
—
—
6
20
371
3761
20
83
321
3334
Neurology
13 [38004458]
-1.4e-01
2.3e-01
—
—
—
8.9e-01
3.7e-01
cases:5.73%
controls:6.56%
cases:3.39%
controls:2.72%
—
—
—
—
—
—
cases:5.57%
controls:2.35%
cases:8.80%
controls:6.23%
22
251
362
3576
13
104
371
3723
—
—
—
21
89
356
3692
30
213
311
3204
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
3.1e-01
—
—
—
—
8.8e-01
8.9e-01
cases:3.91%
controls:2.90%
—
—
—
—
—
—
—
—
cases:1.33%
controls:0.56%
cases:6.16%
controls:2.63%
15
111
369
3716
—
—
—
—
5
21
372
3760
21
90
320
3327
naproxcinod
M01AE18 [40254094]
4.9e-01
8.7e-01
—
—
—
3.9e-01
3.4e-01
cases:11.46%
controls:7.34%
cases:5.21%
controls:2.25%
—
—
—
—
—
—
cases:3.18%
controls:2.17%
cases:10.26%
controls:7.52%
44
281
340
3546
20
86
364
3741
—
—
—
12
82
365
3699
35
257
306
3160
naproxen; oral, rectal
M01AE02 [21603968]
4.9e-01
8.7e-01
—
—
—
3.9e-01
3.4e-01
cases:11.46%
controls:7.34%
cases:5.21%
controls:2.25%
—
—
—
—
—
—
cases:3.18%
controls:2.17%
cases:10.26%
controls:7.52%
44
281
340
3546
20
86
364
3741
—
—
—
12
82
365
3699
35
257
306
3160
roxithromycin; oral
J01FA06 [21602974]
8.7e-01
—
—
—
—
—
5.6e-01
cases:8.33%
controls:3.68%
—
—
—
—
—
—
—
—
—
—
cases:5.28%
controls:3.07%
32
141
352
3686
—
—
—
—
—
18
105
323
3312
propranolol; oral, parenteral
C07AA05 [21601670]
3.1e-01
5.4e-01
—
—
—
6.5e-01
8.4e-01
cases:4.43%
controls:3.29%
cases:2.08%
controls:1.23%
—
—
—
—
—
—
cases:2.65%
controls:1.40%
cases:7.62%
controls:3.45%
17
126
367
3701
8
47
376
3780
—
—
—
10
53
367
3728
26
118
315
3299
Thorax X-ray examination
GD1AA [2001303617]
8.3e-01
-3.4e-03
—
—
-1.0e+50
8.7e-01
5.9e-01
cases:7.81%
controls:3.55%
cases:1.30%
controls:1.31%
—
—
—
—
cases:0.00%
controls:0.16%
cases:2.92%
controls:1.24%
cases:8.80%
controls:5.06%
30
136
354
3691
5
50
379
3777
—
—
0
6
383
3815
11
47
366
3734
30
173
311
3244
escitalopram; oral
N06AB10 [21604718]
7.9e-01
7.8e-01
—
—
1.4e+00
6.8e-01
7.4e-01
cases:6.25%
controls:2.93%
cases:3.91%
controls:1.83%
—
—
—
—
cases:1.57%
controls:0.39%
cases:3.45%
controls:1.77%
cases:6.74%
controls:3.34%
24
112
360
3715
15
70
369
3757
—
—
6
15
377
3806
13
67
364
3714
23
114
318
3303
antibiotics in combination with other drugs
S01AA20 [21603571]
1.9e-01
5.6e-01
—
—
-1.0e+50
5.4e-01
7.7e-01
cases:5.21%
controls:4.34%
cases:1.82%
controls:1.05%
—
—
—
—
cases:0.00%
controls:0.16%
cases:2.12%
controls:1.24%
cases:8.21%
controls:3.98%
20
166
364
3661
7
40
377
3787
—
—
0
6
383
3815
8
47
369
3734
28
136
313
3281
tizanidine; oral
M03BX02 [21604116]
3.1e-01
1.1e-01
1.3e+00
—
1.1e+00
7.7e-01
4.1e-01
cases:15.89%
controls:12.20%
cases:4.69%
controls:4.23%
cases:1.56%
controls:0.44%
—
—
cases:1.31%
controls:0.42%
cases:7.96%
controls:3.86%
cases:19.94%
controls:14.14%
61
467
323
3360
18
162
366
3665
6
17
378
3810
—
5
16
378
3805
30
146
347
3635
68
483
273
2934
desloratadine; oral
R06AX27 [21603526]
4.6e-01
3.1e-01
—
—
—
3.7e-01
7.4e-01
cases:5.73%
controls:3.71%
cases:2.86%
controls:2.12%
—
—
—
—
—
—
cases:2.92%
controls:2.04%
cases:8.80%
controls:4.42%
22
142
362
3685
11
81
373
3746
—
—
—
11
77
366
3704
30
151
311
3266
mometasone; nasal
R01AD09 [21605051]
-1.3e-01
1.7e-01
—
—
—
1.6e-01
6.7e-01
cases:6.51%
controls:7.34%
cases:3.39%
controls:2.87%
—
—
—
—
—
—
cases:3.18%
controls:2.72%
cases:13.20%
controls:7.20%
25
281
359
3546
13
110
371
3717
—
—
—
12
103
365
3678
45
246
296
3171
General Practice
1 [38004446]
1.6e-01
-1.8e-01
-1.0e+50
1.0e+50
—
5.5e-01
5.8e-01
cases:8.59%
controls:7.42%
cases:2.08%
controls:2.48%
cases:0.00%
controls:0.52%
cases:1.56%
controls:0.00%
—
—
cases:4.77%
controls:2.80%
cases:14.37%
controls:8.60%
33
284
351
3543
8
95
376
3732
0
20
384
3807
6
0
378
3827
—
18
106
359
3675
49
294
292
3123
Internal Medicine
11 [38004456]
2.2e-01
-1.1e-01
9.1e-01
—
6.8e-01
4.9e-01
5.2e-01
cases:17.45%
controls:14.53%
cases:5.47%
controls:6.06%
cases:3.13%
controls:1.28%
—
—
cases:2.09%
controls:1.07%
cases:8.75%
controls:5.53%
cases:22.58%
controls:14.75%
67
556
317
3271
21
232
363
3595
12
49
372
3778
—
8
41
375
3780
33
209
344
3572
77
504
264
2913
Health maint/preventive medicine
A98 [2002000231]
1.7e-01
2.1e-01
5.1e-01
—
-4.0e-02
4.5e-01
3.1e-01
cases:26.30%
controls:23.07%
cases:17.71%
controls:14.89%
cases:4.17%
controls:2.53%
—
—
cases:2.09%
controls:2.17%
cases:22.28%
controls:15.42%
cases:41.35%
controls:34.06%
101
883
283
2944
68
570
316
3257
16
97
368
3730
—
8
83
375
3738
84
583
293
3198
141
1164
200
2253
Anion gap in Blood by calculation
41276-7 [3039000]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
cases:0.00%
controls:0.38%
0
7
384
3820
—
—
—
—
0
5
377
3776
0
13
341
3404
Thorax CT examination
GD1AD [2001303618]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
9
341
3408
isosorbide mononitrate; oral
C01DA14 [21600324]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
0
6
384
3821
—
—
—
—
Angina pectoris, unspecified
I20.99 [2000502407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
384
3819
—
—
—
—
—
—
Opening and preparing the root canals, extremely complicated And time consuming
SGA05 [2001310383]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
0
8
377
3773
—
Examination of eyes and vision
Z01.0 [45566391]
2.9e-01
—
—
—
—
—
1.9e-01
cases:1.56%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
cases:2.64%
controls:2.19%
6
45
378
3782
—
—
—
—
—
9
75
332
3342
Migraine, unspecified
G43.9 [45595943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
12
341
3405
Coronary angiography
AN1 [2000200163]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
27
384
3800
0
7
384
3820
—
—
—
—
0
11
341
3406
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
0
5
377
3776
—
Gastro-oesophageal reflux disease
K21 [45586708]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
0
5
384
3822
—
—
—
—
—
Care involving use of rehabilitation procedure, unspecified
Z50.9 [45595525]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
0
7
377
3774
—
fluticasone; inhalant
R03BA05 [21603288]
1.7e-01
—
—
—
—
—
-3.3e-01
cases:1.82%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:2.02%
7
59
377
3768
—
—
—
—
—
5
69
336
3348
Acute tubulo-interstitial nephritis
N10 [45543856]
1.4e+00
—
—
—
—
—
—
cases:1.56%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
6
15
378
3812
—
—
—
—
—
—
Irradiated enamel
K03.80 [2000502698]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
0
15
384
3812
—
—
—
—
0
7
377
3774
—
Schizophrenia
P72 [2002000866]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.21%
—
—
cases:0.00%
controls:0.18%
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.61%
0
20
384
3807
0
14
384
3813
0
8
384
3819
—
0
7
383
3814
0
12
377
3769
0
21
341
3396
Dysphagia
R13 [45573013]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
0
10
384
3817
—
—
—
—
0
6
377
3775
—
Health check-up due to individual need in students of upper secondary schools or vocational schools
SPAT1367 [2001700468]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
384
3821
—
—
—
—
—
—
Fracture of clavicle
S42.0 [45578284]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
0
7
384
3820
—
—
—
—
—
0
6
341
3411
Epicardial ultrasonography
XFE00 [2001303343]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
384
3822
—
—
—
—
—
—
Procedure duration 0 to 9 minutes
ZXE01 [2001311395]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
384
3820
—
—
—
—
—
—
Hypertension uncomplicated
K86 [2002000613]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.34%
cases:0.00%
controls:0.16%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
0
13
384
3814
0
6
384
3821
—
—
—
0
8
377
3773
—
Preventive oral health care, extensive
SCA03 [2001310304]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
0
15
384
3812
—
—
—
—
—
0
5
341
3412
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
3.8e-01
—
—
—
—
1.2e+00
5.8e-01
cases:2.60%
controls:1.80%
—
—
—
—
—
—
—
—
cases:1.86%
controls:0.58%
cases:2.64%
controls:1.49%
10
69
374
3758
—
—
—
—
7
22
370
3759
9
51
332
3366
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
—
—
—
—
—
—
4.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.76%
controls:1.17%
—
—
—
—
—
—
6
40
335
3377
Other general examinations
Z00.8 [45581001]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
0
7
377
3774
—
Removal of internal fixation device from wrist or hand
NDU20 [2001307764]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
384
3822
—
—
—
—
—
—
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
0
8
384
3819
—
0
5
383
3816
—
—
Angiography of the heart and coronary arteries
81 [2002100125]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.29%
0
6
384
3821
—
—
—
—
0
6
377
3775
0
10
341
3407
topiramate; oral
N03AX11 [21604433]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.39%
cases:0.00%
controls:0.16%
—
—
—
—
—
—
cases:0.00%
controls:0.21%
cases:0.00%
controls:0.23%
0
15
384
3812
0
6
384
3821
—
—
—
0
8
377
3773
0
8
341
3409
Ankle X-ray examination without contrast
NH1AA [2001308235]
—
—
—
—
—
—
7.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.67%
—
—
—
—
—
—
5
23
336
3394
prednisolone; oral, parenteral
H02AB06 [21602734]
3.4e-01
5.2e-01
—
—
-1.0e+50
5.8e-01
2.6e-01
cases:7.29%
controls:5.28%
cases:3.65%
controls:2.19%
—
—
—
—
cases:0.00%
controls:0.24%
cases:3.98%
controls:2.27%
cases:8.21%
controls:6.47%
28
202
356
3625
14
84
370
3743
—
—
0
9
383
3812
15
86
362
3695
28
221
313
3196
Pathology report gross observation
24419-4 [3002256]
—
—
—
—
—
—
9.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.64%
controls:1.08%
—
—
—
—
—
—
9
37
332
3380
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
-1.0e+50
—
—
—
—
-1.0e+50
8.3e-01
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
cases:1.47%
controls:0.64%
0
12
384
3815
—
—
—
—
0
13
377
3768
5
22
336
3395
Melanocytic naevi
D22 [45595739]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.50%
—
—
—
—
—
—
5
17
336
3400
dexamethasone
S03BA01 [21605201]
4.3e-01
—
—
—
—
—
8.1e-01
cases:2.34%
controls:1.54%
—
—
—
—
—
—
—
—
—
—
cases:3.23%
controls:1.46%
9
59
375
3768
—
—
—
—
—
11
50
330
3367
ergotamine; inhalant, oral, parenteral, rectal, sublingual
N02CA02 [21604367]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
384
3822
—
—
—
—
—
—
Immunoglobulin light chains.free panel - Serum
57778-3 [40760888]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
0
6
341
3411
Repair of obstetric laceration of vagina
MBC10 [2001306946]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
7
341
3410
pseudoephedrine, combinations; oral
R01BA52 [21603213]
1.7e-01
1.2e-01
—
—
—
2.6e-01
2.5e-01
cases:11.46%
controls:9.85%
cases:3.39%
controls:3.00%
—
—
—
—
—
—
cases:4.77%
controls:3.73%
cases:12.02%
controls:9.66%
44
377
340
3450
13
115
371
3712
—
—
—
18
141
359
3640
41
330
300
3087
Erythrocyte [DistWidth] in Red Blood Cells by Automated count
788-0 [3019897]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
384
3821
—
—
—
—
—
—
Overexertion and strenuous or repetitive movements
X50 [45756406]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
384
3821
—
—
—
—
—
—
Presence of aortocoronary bypass graft
Z95.1 [45556881]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
7
341
3410
Other and unspecified convulsions
R56.8 [45602033]
—
—
—
—
—
—
9.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.56%
—
—
—
—
—
—
5
19
336
3398
Benign neoplasm: Skin of lower limb, including hip
D23.7 [45581295]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
5
341
3412
Schizophrenia
F20 [45542835]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
0
5
384
3822
—
—
—
—
—
0
7
341
3410
Therapeutic discussion
SPAT1240 [2001700341]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
9
384
3818
—
0
10
383
3811
—
—
celiprolol; oral
C07AB08 [21601690]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
cases:0.00%
controls:0.18%
0
5
384
3822
—
—
—
—
0
5
377
3776
0
6
341
3411
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
2.7e-01
—
—
—
—
—
3.5e-01
cases:2.34%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
cases:6.45%
controls:4.62%
9
69
375
3758
—
—
—
—
—
22
158
319
3259
chloramphenicol
D10AF03 [21602307]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.35%
controls:0.73%
—
—
—
—
—
—
8
25
333
3392
Biopsy of prostate with ultrasoudnguidance
KE1AT [2001306172]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
384
3820
—
—
—
—
—
—
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
—
—
—
—
—
-1.0e+50
5.5e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:2.05%
controls:1.20%
—
—
—
—
—
0
6
377
3775
7
41
334
3376
Other specified intervertebral disc degeneration
M51.3 [45591865]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
0
5
384
3822
—
—
—
0
7
377
3774
—
Mitral (valve) insufficiency
I34.09 [2000502484]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
7
384
3820
—
—
—
—
—
0
9
341
3408
Other local analgesia
WX199 [2001310775]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
5
341
3412
Assessment of need for oral health care, standard
SAD01 [2001310287]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
0
12
384
3815
—
—
—
—
—
flecainide; oral, parenteral
C01BC04 [21600266]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
0
6
384
3821
0
6
384
3821
—
—
—
—
0
7
341
3410
Alcohol dependence currently abstinent but using aversion-inducing or inhibitory medication
F10.23 [2000501680]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
5
341
3412
fluticasone, combinations
R01AD58 [43534837]
4.7e-01
—
-1.0e+50
—
—
-1.5e-01
2.7e-01
cases:4.17%
controls:2.64%
—
—
cases:0.00%
controls:0.26%
—
—
—
—
cases:1.33%
controls:1.53%
cases:4.69%
controls:3.63%
16
101
368
3726
—
0
10
384
3817
—
—
5
58
372
3723
16
124
325
3293
Skin infection other
S76 [2002001040]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
0
11
384
3816
—
—
—
—
0
7
377
3774
—
Periodontal treatment by dental hygienist
SDE02 [2001310350]
2.3e-01
1.5e+00
—
—
—
—
-3.1e-01
cases:3.13%
controls:2.51%
cases:1.56%
controls:0.37%
—
—
—
—
—
—
—
—
cases:1.47%
controls:1.99%
12
96
372
3731
6
14
378
3813
—
—
—
—
5
68
336
3349
fluticasone; nasal
R01AD08 [21605050]
2.3e-01
1.3e-01
—
—
—
4.0e-01
2.4e-01
cases:8.59%
controls:6.92%
cases:3.39%
controls:2.98%
—
—
—
—
—
—
cases:3.98%
controls:2.70%
cases:8.80%
controls:7.02%
33
265
351
3562
13
114
371
3713
—
—
—
15
102
362
3679
30
240
311
3177
Myeloperoxidase IgG Ab [Units/volume] in Serum
48404-8 [3049804]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
0
7
384
3820
—
—
—
—
—
Fetal chromosomal abnormality screening
472825005 [43020943]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
6
384
3821
—
—
—
—
—
0
11
341
3406
Persons encountering health services in other specified circumstances
Z76.8 [45542457]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
0
7
384
3820
—
—
—
—
—
nilvadipine; oral
C08CA10 [21601756]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
5
341
3412
Phosphatidylethanol [Mass/volume] in Blood
74661-0 [44816559]
—
-1.0e+50
—
—
—
—
3.8e-01
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:2.64%
controls:1.81%
—
0
9
384
3818
—
—
—
—
9
62
332
3355
Repair of umbilical hernia using prosthetic material
JAF30 [2001304444]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
384
3822
—
—
—
—
—
—
chlorphenamine, combinations
R06AB54 [21603468]
2.5e-02
—
—
—
—
—
6.6e-02
cases:2.86%
controls:2.80%
—
—
—
—
—
—
—
—
—
—
cases:2.93%
controls:2.75%
11
107
373
3720
—
—
—
—
—
10
94
331
3323
Treatment plan or consultation
WZC00 [2001310885]
6.1e-01
—
-1.0e+50
—
—
—
5.1e-01
cases:5.21%
controls:2.90%
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
cases:6.16%
controls:3.78%
20
111
364
3716
—
0
5
384
3822
—
—
—
21
129
320
3288
hepatitis B, purified antigen
J07BC01 [21601338]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
0
5
384
3822
—
—
—
—
—
Anxiety disorder, unspecified
F41.9 [45542849]
4.9e-01
1.5e+00
—
—
—
—
4.8e-01
cases:2.08%
controls:1.28%
cases:1.56%
controls:0.37%
—
—
—
—
—
—
—
—
cases:2.35%
controls:1.46%
8
49
376
3778
6
14
378
3813
—
—
—
—
8
50
333
3367
Fear sexually transm dis female
X23 [2002001308]
1.4e+00
—
—
—
—
—
—
cases:1.30%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
5
12
379
3815
—
—
—
—
—
—
Second degree haemorrhoids
K64.1 [45572223]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
0
7
377
3774
—
Iron deficiency anaemia secondary to blood loss (chronic)
D50.0 [45566697]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.18%
0
5
384
3822
—
—
—
—
—
0
6
341
3411
Unspecified human immunodeficiency virus [HIV] disease
B24 [45547443]
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
cases:4.95%
controls:0.00%
cases:4.43%
controls:0.00%
cases:2.08%
controls:0.00%
cases:2.34%
controls:0.00%
cases:3.13%
controls:0.00%
cases:4.77%
controls:0.00%
cases:7.33%
controls:0.00%
19
0
365
3827
17
0
367
3827
8
0
376
3827
9
0
375
3827
12
0
371
3821
18
0
359
3781
25
0
316
3417
Very extensive body CT
JN4CD [2001310902]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
384
3822
—
—
—
—
—
—
Other cells [#/volume] in Blood by Manual count
51585-8 [3041806]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
384
3819
—
—
—
—
—
—
Leiomyoma of uterus, unspecified
D25.9 [45542693]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
384
3818
—
—
—
—
—
—
betamethasone
S02BA07 [21605169]
6.2e-01
3.3e-01
2.1e+00
—
-1.0e+50
9.6e-01
5.6e-01
cases:8.33%
controls:4.68%
cases:2.34%
controls:1.70%
cases:1.30%
controls:0.16%
—
—
cases:0.00%
controls:0.24%
cases:3.98%
controls:1.56%
cases:8.50%
controls:5.03%
32
179
352
3648
9
65
375
3762
5
6
379
3821
—
0
9
383
3812
15
59
362
3722
29
172
312
3245
dextromethorphan; oral
R05DA09 [21603404]
-2.2e-01
—
—
—
—
-1.0e+50
—
cases:1.56%
controls:1.93%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
6
74
378
3753
—
—
—
—
0
14
377
3767
—
Necrosis of pulp
K04.1 [45572186]
1.7e-01
-1.0e+50
—
—
—
—
—
cases:1.30%
controls:1.10%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
5
42
379
3785
0
11
384
3816
—
—
—
—
—
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
313 [2001600274]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
384
3822
—
—
—
—
—
—
Suture or reinsertation of rotator cuff of shoulder
NBL00 [2001307341]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
16
341
3401
Lupus anticoagulant aPTT and dRVVT screening panel W Reflex
75515-7 [46235128]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
5
341
3412
Hereditary retinal dystrophy
H35.5 [45552678]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
5
341
3412
Contraceptive management, Sterilisation
V252A [2000409180]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
384
3820
—
—
—
—
—
—
Chronic arrhythmias
207 [2001600205]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
20
341
3397
ECG with 12 standard connections
XF400 [2001303368]
2.5e-01
—
—
—
—
—
1.0e+00
cases:1.30%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:2.05%
controls:0.73%
5
39
379
3788
—
—
—
—
—
7
25
334
3392
dexamethasone
D10AA03 [21602286]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.64%
controls:0.85%
—
—
—
—
—
—
9
29
332
3388
Pain, unspecified
R52.9 [45544151]
—
—
—
—
—
—
5.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.47%
controls:0.88%
—
—
—
—
—
—
5
30
336
3387
Other reason for encounter NEC
-69 [2002000140]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.13%
—
—
—
—
—
—
—
—
—
—
—
0
5
384
3822
—
—
—
—
—
hyaluronic acid
S01KA01 [21605114]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
0
11
384
3816
—
—
—
—
—
0
8
341
3409
fluocortolone
C05AA08 [21601612]
6.4e-01
—
—
—
—
—
3.6e-01
cases:1.82%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
cases:1.76%
controls:1.23%
7
37
377
3790
—
—
—
—
—
6
42
335
3375
Bloodpressure measurement
XF600 [2001303376]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
0
6
377
3775
—
ramipril; oral
C09AA05 [21601789]
-7.1e-01
-7.9e-01
-1.0e+50
—
—
-5.7e-01
-7.6e-01
cases:1.56%
controls:3.14%
cases:1.30%
controls:2.82%
cases:0.00%
controls:0.86%
—
—
—
—
cases:1.59%
controls:2.78%
cases:2.05%
controls:4.30%
6
120
378
3707
5
108
379
3719
0
33
384
3794
—
—
6
105
371
3676
7
147
334
3270
Irrigation or wax removal of outer auditory canal
SPAT1033 [2001700134]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
0
15
384
3812
—
—
—
0
17
377
3764
—
Episiotomy
TMA00 [2001306920]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.15%
—
—
—
—
—
—
0
5
341
3412

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
252
74
75.09
307.65
13.5
1.9
9.27
—
titre
—
128
0
173
133
20.37
193.02
6.5
3.9
143.27
351.56
mg/l
1.31
151
64
111
34
42.86
178.29
2.9
2.3
32.22
34.65
%
0.40
111
34
105
28
48.45
174.86
2.8
3.1
28.30
40.70
%
2.30
15
15
237
374
12.14
161.92
5.0
1.7
—
—
—
0
0
247
572
8.26
115.00
6.6
1.7
—
—
—
0
0
173
386
6.62
79.72
5.1
1.5
—
—
—
0
0
146
379
5.20
54.74
2.2
3.1
32.21
43.73
u/l
0.47
141
325
62
87
8.09
43.04
1.2
1.1
—
—
—
0
0
210
835
3.81
42.90
4.2
3.4
—
0.00
—
0
8
202
872
3.37
34.80
10.0
1.9
—
—
—
0
0
262
1332
3.28
34.07
4.7
3.8
16.26
97.24
e6/l
1.74
138
954
57
95
6.72
33.67
1.2
1.1
—
—
—
0
0
67
141
5.40
31.02
1.3
1.5
235.37
226.07
miu/ml
0.05
22
74
228
1120
3.08
30.55
8.8
6.0
—
—
—
0
0
240
1267
2.89
27.35
11.3
6.6
—
—
—
0
0
143
617
2.92
23.07
2.2
2.9
0.83
0.86
e6/l
0.04
53
320
334
2211
2.92
23.02
13.5
10.2
3.72
4.15
e9/l
3.03
298
1934
148
662
2.83
22.21
2.1
1.7
—
—
—
0
0
306
1975
2.68
21.47
12.5
6.8
0.58
0.59
e9/l
0.03
280
1715
306
1978
2.67
21.35
12.5
6.8
0.04
0.04
e9/l
0.58
280
1719
309
2016
2.66
21.00
12.5
7.0
2.07
1.97
e9/l
0.68
283
1804
288
1824
2.58
20.71
13.0
7.1
8.97
8.81
%
0.53
279
1740
290
1849
2.57
20.46
12.7
6.8
52.65
57.17
%
9.10
282
1787
286
1812
2.56
20.44
13.1
6.9
2.78
2.92
%
0.61
277
1725
310
2043
2.62
20.33
12.5
7.2
0.19
0.20
e9/l
0.67
283
1812
285
1807
2.54
20.27
13.1
7.1
0.74
0.69
%
1.15
276
1714
185
961
2.56
20.26
2.6
3.0
—
0.00
estimate
—
0
6
131
574
2.80
20.21
2.2
3.0
2.61
1.16
e6/l
0.46
41
276
264
1621
2.50
20.06
4.1
3.1
6.14
6.12
ph
0.06
88
978
291
1873
2.54
19.88
12.9
6.9
32.72
27.81
%
9.84
283
1799
187
1012
2.44
18.36
2.7
3.1
0.23
0.34
e6/l
0.77
114
736
255
1585
2.39
18.23
5.3
5.5
37.79
36.58
g/l
2.60
241
1511
47
118
4.33
17.38
1.6
1.2
—
—
—
0
0
301
2039
2.41
17.29
7.8
7.0
13.43
12.26
umol/l
0.43
293
1949
201
1172
2.28
16.13
2.9
3.2
17.56
101.87
e6/l
0.88
130
895
262
1725
2.22
15.35
15.5
11.0
0.00
0.00
e9/l
0.47
221
1412
286
1991
2.18
14.04
4.1
3.3
0.00
0.00
estimate
-0.00
30
404
287
2012
2.15
13.69
4.1
3.3
0.00
3.97
estimate
0.50
30
409
287
2018
2.14
13.50
4.2
3.3
0.00
0.03
estimate
1.06
27
362
226
1480
2.05
12.55
11.1
3.4
37.19
35.74
u/l
0.08
217
1411
367
2887
2.40
12.50
9.8
8.7
76.99
78.40
u/l
0.29
361
2770
34
94
3.83
11.01
2.2
1.1
—
—
—
0
0
86
440
2.18
8.82
1.7
1.7
—
—
—
0
0
233
1694
1.77
8.16
2.2
1.9
1.42
1.49
mmol/l
0.65
220
1479
429
3853
2.98
7.39
15.6
14.7
26.16
24.05
mg/l
0.68
375
3121
18
42
4.42
7.28
2.1
1.8
—
—
—
0
0
17
41
4.27
6.60
2.1
1.5
—
—
—
0
0
26
89
3.04
6.10
1.8
1.4
—
—
—
0
0
133
1871
0.59
5.99
3.2
3.0
—
—
—
0
0
45
207
2.30
5.92
1.2
1.2
—
—
—
0
0
25
87
2.98
5.71
2.3
3.6
2.33
2.81
index
—
6
58
30
119
2.63
5.41
1.8
3.8
—
—
—
0
0
81
495
1.77
4.84
1.6
1.5
—
—
—
0
0
179
1342
1.55
4.77
3.2
3.7
8.92
8.71
mmol/l
0.18
158
1165
32
145
2.30
4.39
2.2
3.1
1.11
1.34
mg/l
2.16
27
134
45
235
2.02
4.34
2.8
3.4
23.71
24.37
mmol/l
0.58
45
235
104
700
1.63
4.33
2.5
2.5
15.62
14.58
nmol/l
0.64
99
661
50
274
1.93
4.21
1.6
2.6
—
—
—
0
0
113
800
1.55
3.76
2.6
2.5
3.79
4.19
e6/l
0.21
104
732
54
316
1.80
3.72
2.0
2.0
39.72
36.72
nmol/l
0.40
54
308
23
97
2.44
3.71
1.9
1.4
26.60
24.50
e6/l
0.04
15
70
28
132
2.19
3.53
1.3
1.1
—
—
—
0
0
138
1033
1.48
3.51
4.4
4.6
—
—
—
0
0
6
6
10.11
3.50
3.2
1.5
—
—
—
0
0
23
100
2.37
3.49
1.9
1.5
537.87
990.45
e6/l
0.22
15
73
47
269
1.83
3.49
1.7
1.7
0.23
0.35
mg/l
1.26
26
135
86
583
1.59
3.44
2.4
2.2
—
—
—
0
0
50
296
1.77
3.33
1.6
2.5
—
—
—
0
0
50
296
1.77
3.33
1.6
2.5
—
—
—
0
0
126
935
1.48
3.32
1.7
1.6
20.41
19.75
nmol/l
0.22
114
809
438
4164
2.39
3.26
24.6
18.0
79.09
80.51
umol/l
0.70
438
4135
49
291
1.77
3.23
1.6
2.6
—
—
—
0
0
15
55
2.79
3.18
1.0
1.2
—
—
—
0
0
15
55
2.79
3.18
1.1
1.1
1.83
1.20
eliau/ml
—
6
24
30
154
2.01
3.07
1.2
1.3
—
—
—
0
0
8
16
5.07
3.06
5.0
2.0
35.50
34.81
%
—
8
16
88
624
1.51
2.87
3.0
3.0
2.43
2.44
mmol/l
0.21
75
558
189
1546
1.38
2.83
6.6
7.6
1.20
1.21
mmol/l
0.62
177
1460
12
39
3.13
2.79
1.0
1.1
—
—
—
0
0
17
72
2.41
2.76
2.0
2.7
1.84
2.18
mmol/l
0.36
12
48
150
1185
1.40
2.75
2.4
2.4
—
—
—
0
0
11
34
3.29
2.74
1.0
1.1
—
—
—
0
0
396
3684
1.58
2.74
6.3
4.7
5.98
5.96
mmol/l
0.09
377
3470
14
54
2.64
2.73
1.4
1.5
196.17
166.12
pmol/l
0.71
14
54
27
140
1.99
2.71
1.1
1.3
—
—
—
0
0
27
140
1.99
2.71
4.2
11.1
—
—
—
0
0
397
3698
1.58
2.70
7.2
5.8
37.94
39.03
mmol/mol
0.47
387
3543
132
1028
1.40
2.62
3.5
4.2
7.40
7.40
ph
0.00
78
733
47
294
1.67
2.60
1.6
2.3
—
—
—
0
0
5
7
7.21
2.55
3.6
1.7
—
—
—
0
0
65
443
1.55
2.54
1.3
1.2
—
—
—
0
0
43
266
1.68
2.49
1.8
2.0
237.16
222.14
pmol/l
0.42
43
254
89
1180
0.69
2.46
3.0
2.7
0.00
0.00
estimate
0.50
23
324
94
697
1.44
2.44
2.5
2.7
584.99
559.45
mosm/kgh2o
0.44
82
614
178
1470
1.35
2.42
2.2
2.0
97.15
95.96
pmol/l
0.13
108
799
23
118
2.00
2.40
1.1
1.1
—
—
—
0
0
108
825
1.41
2.38
1.5
1.4
2.64
2.54
g/l
0.21
60
562
23
119
1.98
2.35
1.1
1.1
—
—
—
0
0
77
554
1.47
2.34
1.4
1.4
422.86
342.26
titre
0.32
14
106
17
78
2.23
2.34
2.4
2.8
—
—
—
0
0
410
3883
1.57
2.17
16.8
16.9
3.94
3.99
mmol/l
2.99
402
3821
184
1552
1.31
2.10
2.5
2.5
77.06
73.90
nmol/l
0.74
170
1432
142
1159
1.33
2.04
3.3
3.6
2.36
2.35
mmol/l
0.35
128
1069
105
825
1.35
1.93
2.3
2.1
2.82
2.79
mg/l
0.05
92
722
29
177
1.68
1.81
1.5
1.5
6.30
6.16
u/l
0.03
21
148
159
1340
1.29
1.77
2.3
2.0
—
—
—
0
0
44
301
1.51
1.73
1.2
1.2
—
—
—
0
0
7
24
2.95
1.73
1.0
1.3
135.86
155.06
nmol/l
—
7
24
50
355
1.46
1.65
2.0
2.7
0.22
0.22
g/l
0.13
45
332
8
175
0.45
1.61
5.1
7.7
1.80
1.61
%
—
8
161
50
358
1.45
1.59
8.5
11.3
—
—
—
0
0
192
1676
1.25
1.56
2.8
2.8
144.66
153.19
ug/l
0.20
184
1599
75
580
1.35
1.53
1.9
1.4
—
—
—
0
0
96
772
1.31
1.51
3.0
2.8
—
—
—
0
0
9
37
2.46
1.48
1.1
1.2
40.27
53.98
mg/l
—
9
26
33
222
1.52
1.43
1.2
2.4
—
—
—
0
0
37
522
0.68
1.42
1.6
1.5
—
—
—
0
0
91
737
1.29
1.36
3.2
3.5
1393.62
727.50
ng/l
0.21
66
540
0
37
0.00
1.35
0.0
1.5
—
77.65
—
0
37
0
40
0.00
1.33
0.0
2.6
—
1.18
—
0
40
0
40
0.00
1.33
0.0
2.6
—
106.10
—
0
40
0
40
0.00
1.33
0.0
2.6
—
4.06
—
0
40
441
4307
1.78
1.32
27.1
21.5
250.84
245.46
e9/l
0.97
433
4248
10
48
2.11
1.28
1.1
1.8
8.25
11.03
%
—
10
48
300
2784
1.23
1.28
3.7
3.7
14.66
14.68
pmol/l
0.04
282
2581
8
36
2.24
1.25
1.1
1.1
274.13
261.00
mg/l
—
8
28
6
25
2.42
1.24
1.7
3.4
966.00
736.84
u/ml
—
6
25
441
4313
1.73
1.22
27.1
21.5
6.76
6.63
e9/l
0.57
428
4246
441
4313
1.73
1.22
27.1
21.4
4.59
4.69
e12/l
4.21
428
4246
25
165
1.55
1.20
1.2
1.4
—
11.45
—
0
6
195
1742
1.21
1.20
6.5
8.3
1.20
1.21
mmol/l
0.19
170
1545
8
38
2.12
1.19
2.8
1.3
0.57
0.41
g/l
—
8
25
8
38
2.12
1.19
2.8
1.3
6.35
7.18
g/l
—
8
26
8
39
2.07
1.16
2.8
1.3
—
—
—
0
0
5
20
2.52
1.15
1.0
1.0
—
—
—
0
0
7
30
2.35
1.12
1.9
1.6
—
—
—
0
0
7
30
2.35
1.12
1.0
1.3
—
—
—
0
0
120
1028
1.23
1.12
2.6
2.7
355.85
361.99
umol/l
0.32
112
932
59
466
1.31
1.08
8.0
11.1
7.42
7.42
ph
0.26
34
253
106
900
1.23
1.07
3.2
3.4
1.02
1.02
kg/l
1.33
49
581
69
558
1.28
1.06
8.2
8.7
104.64
104.02
mmol/l
0.64
69
558
5
22
2.29
1.03
1.2
1.1
656.08
161.98
iu/ml
—
5
22
30
214
1.43
1.02
1.5
1.2
—
—
—
0
0
14
83
1.71
1.02
1.1
1.0
1.86
8.25
u/ml
—
6
51
10
53
1.91
1.02
1.2
1.1
—
—
—
0
0
17
107
1.61
1.01
1.0
1.2
329.67
266.91
u/ml
0.42
12
65
49
381
1.32
1.01
3.3
3.6
0.61
1.83
mmol/l
1.04
44
325
58
463
1.29
0.99
8.2
11.1
0.35
0.98
mmol/l
0.65
50
399
5
23
2.19
0.98
2.6
3.7
89.40
132.17
nmol/l
—
5
23
0
29
0.00
0.98
0.0
1.3
—
—
—
0
0
50
392
1.31
0.97
3.5
3.7
7.37
7.38
ph
0.53
22
226
0
31
0.00
0.96
0.0
1.7
—
6.40
—
0
23
186
1681
1.18
0.96
3.0
2.8
—
—
estimate
—
0
0
0
32
0.00
0.95
0.0
2.8
—
48.06
—
0
32
0
32
0.00
0.95
0.0
5.6
—
8.00
—
0
32
12
70
1.73
0.93
2.3
2.2
0.72
0.99
g/l
0.38
12
56
38
288
1.35
0.93
1.9
2.9
64.62
71.37
e9/l
0.71
26
202
30
219
1.40
0.92
1.2
1.2
24.21
85.71
u/ml
—
8
88
38
289
1.34
0.91
1.1
1.1
—
—
—
0
0
6
30
2.01
0.87
2.7
1.8
—
—
—
0
0
6
30
2.01
0.87
1.7
1.5
—
—
—
0
0
25
179
1.42
0.86
1.3
1.3
—
—
—
0
0
13
80
1.64
0.85
1.2
1.0
8.24
0.70
u/ml
—
7
31
104
903
1.20
0.85
1.4
1.3
1.05
1.34
u/ml
0.28
25
280
11
65
1.71
0.83
1.2
1.0
0.07
0.43
u/ml
—
5
21
6
32
1.89
0.82
1.5
1.5
16100.00
31021.06
e6/l
—
6
16
14
90
1.57
0.79
2.6
3.4
53.64
58.35
%
0.82
14
90
6
34
1.77
0.76
1.0
2.7
—
—
—
0
0
6
34
1.77
0.76
1.2
1.3
—
—
—
0
0
25
333
0.74
0.75
5.3
5.6
0.00
0.12
%
1.11
11
83
36
282
1.30
0.74
1.6
1.4
—
—
—
0
0
100
878
1.18
0.72
1.8
1.8
1.17
1.22
mg/l
0.08
74
679
25
331
0.74
0.72
5.4
4.9
0.33
0.49
%
0.45
12
102
63
531
1.22
0.71
2.5
3.0
88.00
132.58
ug/g
1.28
52
448
10
157
0.63
0.70
3.1
8.3
3.67
0.88
%
—
10
142
9
58
1.56
0.70
2.8
1.6
—
—
—
0
0
9
58
1.56
0.70
2.8
1.6
—
—
—
0
0
9
58
1.56
0.70
2.8
1.6
—
—
—
0
0
9
58
1.56
0.70
2.8
1.6
—
—
—
0
0
136
1495
0.87
0.66
3.3
3.4
22.34
34.48
ng/l
1.54
81
990
30
233
1.31
0.66
3.8
6.8
—
—
—
0
0
5
28
1.79
0.66
1.0
1.2
—
—
—
0
0
21
155
1.37
0.64
1.6
2.3
132.40
594.27
ug/l
0.97
21
149
12
176
0.67
0.63
4.3
3.4
24.88
24.83
mmol/l
0.03
12
169
0
21
0.00
0.60
0.0
1.5
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
19
140
1.37
0.59
1.1
1.3
—
—
—
0
0
6
36
1.68
0.57
1.5
1.4
2278.67
2397.36
e6/l
—
6
22
6
36
1.68
0.57
1.3
1.1
—
—
—
0
0
11
73
1.52
0.56
1.2
1.0
0.57
2.39
u/ml
—
5
40
6
37
1.63
0.55
1.3
2.6
27.00
33.24
pg
—
6
37
6
39
1.55
0.53
1.3
1.2
—
—
—
0
0
129
1182
1.13
0.53
3.2
3.7
69.03
60.20
mg/l
0.11
80
804
10
66
1.53
0.53
2.0
1.3
—
—
—
0
0
21
161
1.32
0.52
1.5
1.9
1.80
5.58
iu/ml
—
5
35
131
1206
1.12
0.50
3.8
4.4
14.11
9.86
mg/mmol
0.25
82
797
14
102
1.38
0.48
1.1
1.3
—
—
—
0
0
10
68
1.48
0.47
3.4
3.7
3.47
4.28
e9/l
—
10
68
354
3443
1.13
0.47
4.8
4.5
1.80
1.87
mu/l
0.66
338
3221
29
350
0.82
0.45
4.9
4.9
0.84
0.89
%
0.05
16
115
27
220
1.24
0.45
2.6
2.5
0.66
0.66
%
0.01
27
220
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
27
223
1.22
0.40
2.6
2.6
1.25
1.38
%
0.34
27
223
5
34
1.48
0.40
2.0
1.2
102.40
107.94
pmol/l
—
5
34
5
34
1.48
0.40
1.6
1.8
—
—
—
0
0
13
97
1.35
0.40
1.3
1.1
3.37
2.72
u/ml
—
8
54
54
477
1.15
0.39
2.1
3.0
12.05
9.09
umol/l
0.32
46
432
5
35
1.43
0.39
1.0
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
5
37
1.36
0.37
2.0
1.1
—
—
—
0
0
119
1109
1.10
0.36
1.3
1.4
—
—
—
0
0
28
329
0.84
0.35
5.0
5.1
0.00
0.14
%
2.62
15
93
6
44
1.37
0.34
1.0
1.3
—
—
—
0
0
55
494
1.13
0.33
1.6
3.8
4.30
5.80
e9/l
0.70
47
453
10
74
1.36
0.32
1.1
1.6
—
—
—
0
0
11
83
1.33
0.32
2.5
2.2
147.17
133.25
g/l
—
6
59
12
92
1.31
0.32
3.0
2.1
8.78
8.29
kpa
0.68
12
92
27
311
0.86
0.28
1.9
2.3
6.94
9.33
ug/l
0.60
22
283
119
1126
1.08
0.26
2.7
2.7
0.59
0.70
ug/l
0.94
77
583
151
1579
0.93
0.26
3.4
3.1
0.00
0.01
estimate
0.74
23
338
406
4012
1.11
0.26
7.3
5.3
2.80
2.80
mmol/l
0.02
389
3812
9
76
1.19
0.24
1.1
1.2
16.69
16.54
u/l
—
9
68
21
242
0.86
0.23
1.3
1.1
0.71
0.68
ratio
—
6
23
42
460
0.90
0.22
1.4
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
9.69
—
0
12
0
13
0.00
0.21
0.0
1.2
—
66.31
—
0
13
0
14
0.00
0.20
0.0
1.9
—
2.36
—
0
14
0
14
0.00
0.20
0.0
2.2
—
—
—
0
0
6
51
1.18
0.19
2.3
3.3
1.32
2.92
nmol/l
—
6
51
26
288
0.90
0.17
1.9
2.1
5.78
6.08
ph
1.17
16
177
5
70
0.71
0.17
1.0
1.1
—
—
—
0
0
401
3975
1.07
0.16
6.6
4.9
4.61
4.66
mmol/l
0.49
384
3788
22
245
0.89
0.16
12.0
13.4
16.08
16.21
%
0.06
22
235
15
130
1.16
0.16
1.2
2.3
11.14
11.46
mg/l
0.10
15
124
15
170
0.88
0.14
3.3
3.6
—
—
—
0
0
382
3786
1.06
0.13
5.5
4.1
1.41
1.38
mmol/l
0.36
355
3581
166
1701
0.96
0.13
11.0
11.8
1.21
1.19
inr
0.17
126
1412
14
125
1.12
0.10
1.6
1.8
—
—
—
0
0
12
135
0.89
0.10
4.5
2.3
25.27
24.90
mmol/l
0.13
12
135
15
166
0.90
0.10
1.1
1.1
—
—
—
0
0
394
3964
0.95
0.09
6.7
4.8
1.30
1.36
mmol/l
2.40
374
3759
5
46
1.09
0.09
1.0
1.3
—
—
—
0
0
64
617
1.04
0.09
1.2
1.3
13.17
7.31
u/ml
0.23
32
262
5
61
0.82
0.08
2.2
2.7
—
—
—
0
0
7
65
1.08
0.08
2.6
1.5
—
—
—
0
0
6
70
0.86
0.07
1.0
1.1
—
—
—
0
0
6
70
0.86
0.07
1.7
3.1
6.35
8.44
pmol/l
—
6
70
6
72
0.83
0.07
1.8
1.3
—
—
—
0
0
275
2723
1.03
0.07
3.6
3.8
—
0.17
—
0
6
27
286
0.94
0.07
3.8
3.4
—
—
—
0
0
30
285
1.06
0.06
4.0
4.8
7.39
7.34
ph
1.68
19
221
48
496
0.96
0.06
1.6
1.6
1045.00
1212.27
nmol/l
0.75
35
394
186
1839
1.02
0.05
4.7
4.1
2.91
1.75
ug/l
0.69
173
1695
43
443
0.97
0.04
2.0
1.8
3.43
3.55
mmol/l
0.26
31
314
108
1066
1.02
0.03
3.8
3.4
0.00
0.01
estimate
0.69
26
376
16
151
1.06
0.03
1.3
1.6
—
—
—
0
0
69
678
1.02
0.03
1.4
1.7
418.30
19763947.82
pmol/l
0.50
60
592
11
102
1.08
0.03
1.1
2.7
1.07
1.74
ratio
—
6
56
25
259
0.96
0.02
2.6
3.2
120.92
133.08
g/l
1.15
25
250
40
409
0.98
0.02
10.4
11.9
124.77
124.99
g/l
0.02
40
399
21
202
1.04
0.02
1.1
1.6
—
—
—
0
0
12
127
0.94
0.01
2.3
2.7
—
—
—
0
0
127
1261
1.01
0.01
3.0
2.9
63.30
64.86
u/l
0.07
117
1193
25
257
0.97
0.01
3.4
3.3
5.10
5.14
kpa
0.10
25
251
50
493
1.02
0.01
1.1
1.3
—
—
—
0
0
69
683
1.01
0.01
1.5
1.3
39.99
27.11
iu/ml
0.41
20
198
25
246
1.02
0.00
3.4
3.4
7.40
7.42
ph
0.64
19
206
30
304
0.99
0.00
3.1
2.4
0.80
0.18
e6/l
1.02
25
291
15
151
0.99
0.00
1.9
2.2
—
—
—
0
0
404
4043
0.99
0.00
13.3
12.5
—
—
—
0
0
305
3047
1.00
0.00
3.3
3.5
47.18
50.68
u/l
0.35
290
2922
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
9
90
1.00
0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
1.04
—
0
5
0
5
0.00
0.00
0.0
1.2
—
60.00
—
0
5
0
7
0.00
0.00
0.0
1.3
—
2.13
—
0
7
0
5
0.00
0.00
0.0
1.8
—
402.00
—
0
5
5
51
0.98
0.00
1.2
1.2
1.33
1.61
nmol/l
—
5
46
0
5
0.00
0.00
0.0
2.8
—
206.60
—
0
5
0
5
0.00
0.00
0.0
5.8
—
—
—
0
0
97
970
1.00
-0.00
5.2
5.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
70.00
—
0
8
0
8
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
0.41
—
0
9
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
5.7
—
7.22
—
0
9
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
1.21
—
0
8
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
49
1.02
-0.00
3.0
2.3
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint AB1_EARLY_SYPHILIS and mortality.

Females

No data

Males

Parameter HR [95% CI] p-value
AB1_EARLY_SYPHILIS 1.498 [1.19, 1.88] < 0.001
Birth year 0.983 [0.97, 0.99] 0.001

During the follow-up period (1.1.1998 — 31.12.2019), 80 out of 997 males with AB1_EARLY_SYPHILIS died.

Mortality risk

Mortality risk for people of age

years, who have AB1_EARLY_SYPHILIS.

N-year risk Females Males
1 No data 0.299%
5 No data 1.658%
10 No data 4.176%
15 No data 7.743%
20 No data 12.609%

Relationships between endpoints

↥

Index endpoint: AB1_EARLY_SYPHILIS – Early syphilis

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data